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Background: Twenty percent of HIV-infected patients develop HIV-associated 
neurocognitive disorders (HAND), a spectrum of neurological diseases which includes 
HIV-associated dementia (HAD), a debilitating sUb-cortical dementia. HIV-related 
cognitive impairment is a primary neurological complication of HIV infection, as opposed 
to neurological diseases secondary to opportunistic infections in the immune 
compromised host. Neurodegeneration in HAD is attributed to indirect injury mediated 
by an inflammatory process. The mechanisms underlying HAD have not previously 
been studied in a Sub-Saharan population. 
Aims: Our study investigated the role of systemic markers of inflammation and oxidative 
stress, inflammatory changes in the brain on magnetic resonance spectroscopy (MRS) 
and the role of the APOE E4 allele in HIV-associated dementia (HAD) in a South African 
population. We hypothesized that cognitive impairment and brain inflammation would 
correlate with systemic markers of inflammation and oxidative stress; with an inverse 
relation to anti-oxidant capacity. We investigated the APOE E4 allele and its relation to 
markers of systemic and brain inflammation in HAD. 
Methods: We recruited 35 HIV-infected, HAART-na"ive subjects between the ages of 18 
and 35 years, and 10 HIV-negative age- and population-matched controls. Subjects 
were classified into three groups according to degree of cognitive impairment evaluated 











without cognitive impairment (NP 0), HIV- infected subjects with minor cognitive 
impairment (NP 1) and HIV- infected subjects with dementia (NP 2). 
Inflammatory markers tested in serum included tumour necrosis factor alpha (TNF-a), 
interleukin-1 beta (IL-1 13) and transforming growth factor beta (TGF-13). Oxidative stress 
was measured with conjugated dienes (CD), lipid hydroperoxides (LOOH), thiobarbituric 
acid reactive substances (TSARS) and the total anti-oxidant capacity was measured 
with the Oxygen Radical Absorbance Capacity (ORAC). Inflammatory changes in the 
brain were assessed with MRS using N-acetyl aspartate (NAA) and myo-inositol (MI) as 
markers of viable neurons and glial proliferation respectively. APOE genotyping was 
performed to determine the relation of the APOE E4 allele to cognitive impairment in 
HIV-infected subjects. 
Results: Systemic markers of inflammation, the pro-inflammatory cytokine IL-113 in 
particular, correlated significantly with HIV-associated cognitive impairment, oxidative 
stress and MRS measures of inflammation. Markers of systemic oxidative stress 
correlated significantly with brain inflammation on MRS in patients with dementia (NP2). 
We found no relation between the APOE E4 allele and inflammation in HAD, but the 
APOE E2 allele was less frequent in the HIV-infected participants compared to the 
population allelic frequency. 
Conclusion: We found significant associations between systemic inflammatory markers, 
systemic oxidative stress, inflammatory markers in the brain and cognitive impairment in 
HIV-positive subjects. Systemic infection, with associated systemic inflammation, 
oxidative stress and depletion of anti-oxidant defenses, may all play an important role in 
the development of central inflammation and neurodegeneration in HAD. Monitoring of 
this underlying process of inflammation, with markers of systemic inflammation, 
oxidative stress and metabolites on MRS, as explored in this study, may open new 
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The Joint United Nations Programme on HIV/AIDS (UNAIDS) reported in 2008 
that 33.2 million people worldwide were infected with HIV by the end of 2007, of 
which 22 million (67% of the world prevalence) were living in Sub-Saharan 
countries. Human Immunodeficiency Virus (HIV)-associated dementia (HAD) 
affects 40% of HAART-na'ive HIV-infected patients (Boisse, 2008). While most 
published work on HIV-associated neurocognitive disorders (HAND) is derived 
from North American and European studies, a recent report by Wong et a/. 
(Wong, 2007) suggested that the prevalence of cognitive disorders in an HIV 
clinic in Uganda was similar to that reported in U.S. studies. The prevalence of 
HAD and minor cognitive motor disorder (MeMD) in the Uganda study was 31% 
and 45% respectively (Sacktor, 2007; Ellis, 2009), quantifying the extent of HAD 
in Sub-Saharan Africa. 
1.2 The indirect mechanism of neuronal damage 
HIV-associated dementia (HAD) is a primary complication of HIV-1 infection. 
HAD develops due to the direct effects of HIV-1 infection, independent of 
underlying opportunistic infections. As the virus is unable to infect neurons 
directly, neurotoxicity is mediated through an indirect mechanism (Power, 2009). 
HIV-1 displays neurovirulence indirectly through two pathological mechanisms: 
firstly, through activation of microglia, macrophages and astrocytes, with release 
of inflammatory mediators and through oxidative species stress (Boisse, 2008), 
and secondly, through oxidative damage mediated by viral proteins, including 











1.3 Clinical features of HIV-associated dementia 
Clinical features of HIV-associated dementia develop as a result of neuronal 
injury mediated by the HIV infection. HAD affects mainly the basal ganglia and 
deep white matter resulting in a sub-cortical dementia with neurocognitive 
impairment, motor deficits and emotional disturbances (See Table 1 for Clinical 











TABLE 1: Clinical features of HIV-associated neurocognitive disorders 
(HIV-associated dementia and minor neurocognitve disorder) 
.. Neurocognitive dysfunction: Memory impairment, poor concentration, 
psychomotor slowing. 
.. Emotional disturbances: Apathy and social withdrawal, which can be 
mistaken for depression. Also irritability, mental inflexibility, and decreased 
sex drive. 
.. Motor abnormalities: Weakness, ataxia, clumsy gait, slowing motor skills, 
tremor, diffuse increase in tone, hyper reflexia, spasticity, abnormal eye 
movements and parkinsonism. Frontal r lease signs and myoclonus in 
advanced stages of disease. 
.. Brain atrophy and abnormal subcortical white matter signal on magnetic 
resonance imaging and computerized tomography scanning. 
.. Pleocytosis, increased protein and high viral load in cerebrospinal fluid. 











1.4 Classification of HAD 
HIV-associated cognitive impairment is defined as a neurocognitive disorder 
associated with HIV-1 infection in the absence of delirium or another explanation 
for the cognitive impairment. It is classified according to the revised American 
Academy of Neurology criteria. HIV-associated neurocognitive disorders (HAND) 
incorporates three symptom complexes based on the severity of the disease, 
namely asymptomatic neurocognitive impairment (ANI), minor neurocognitive 
disorder (MND) and HIV-associated dementia (HAD). The revised criteria take 
the asymptomatic form of the disease into account and focus on the 
neurocognitive impairment rather than motor, emotional and personality aspects, 
as do previous classifications. 
Neurocognitive impairment is graded on a neuropsychiatric score of less than 1 
standard deviation below the norm in two or more domains of at least five 
domains tested. The patient is then further classified according to the presence 
of symptoms as asymptomatic or mildly symptomatic. The disease is classified 
as severe, or dementia, if the neuropsychiatric score is more than 2 standard 
deviations below the demographically ascertained norm in two or more of the 
cognitive domains tested. The latter is associated with marked difficulty of 
everyday function. 
We devised a similar neuropsychiatric scoring system to evaluate cognitive 












TABLE 2: The National Institute of Neurological Diseases and Stroke (NINDS) 
Classification of HIV-associated neurocognitive disorder (HAND) into three 
broad groups 
1. Asymptomatic Neurocognitive Impairment (ANI) 
• mild impairment of at least 1 Standard Deviation below the norm on 
neuropsychological testing in two or more domains of at least five cognitive 
domains tested 
• without a clear effect on everyday functioning 
2. HIV-associated Mild Neurocognitive Disorder (MND) 
• mild impairment of at least 1 Standard Deviation below the norm on 
neuropsychological testing in two or more domains of at least five cognitive 
domains tested 
• a mild effect on everyday functioning 
3. HIV-associated dementia (HAD) 
• moderate to severe impairment of at least 2 Standard Deviations on 
neuropsychological testing in two or more domains of at least five cognitive 
domains tested 
• substantial effect on everyday functioning 
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After the initiation of highly active antiretroviral treatment (HAART) the incidence 
of HIV-associated dementia decreased, but prolonged survival rates of patients 
on HAART resulted in an increase in prevalence of mild neurocognitive disorder 
(MND). MND develops in 20% of patients despite HAART (McArthur, 2005) and, 
in contrast to the decline in HAD, 30-50% of patients on HAART suffer from MND 
(Ghafouri, 2006; Ellis, 2009). 
HAART attenuates the disease course of HAD and new subtypes of HAD have 
been described as a result. 
.. Sub acute progressive dementia develops in patients who are not on 
HAART and disease progress is similar to HAD in the pre-HAART era. 
develop 
.. Chronic active dementia develops in patients with poor adherence or viral 
resistance, associated with progression of disease. 
.. Chronic inactive dementia is seen in patients with good adherence and 
response to HAART with stable neurological disease. 
.. Reversible dementia is recognized on clinical presentation in patients with 
good HAART adherence (Nath, 2008). 
1.5 Clade diversity 
A diversity of clades, or HIV subtypes, exists. 10% of HIV-1 infections worldwide 
are caused by clade B, mostly affecting European and North American 
populations, while Clade C is responsible for 50 % of the HIV-1 infections in the 
world (Ellis, 2009; Boisse, 2008; Nath, 2008). Most studies on HAD have been 
performed in Western countries with a clade B predominance while clade C is 
most prevalent in Africa. This difference in clades may influence the 
phenotypical expression of HIV associated dementia. Information on clade-











reveal differences in the clinical presentation of HAD in clade C compared with 
clade B. 
1.6 Aims of the study and Hypotheses 
Currently the prevalence of HAD in South Africa is unknown, but our clinical 
experience suggests that the burden of HIV-associated dementia is significant. 
The aim of this study was to contribute to the understanding of mechanisms 
underlying HAD. We investigated systemic inflammation, systemic oxidative 
stress and inflammation in the brain and their role in HAD. We focused on two 
postulated mechanisms of neuronal damage in HIV infection. Firstly, indirect 
neuronal damage caused by cytokines released by activated microglial cells 
during inflammatory processes in the nervous system. The second mechanism 
involves damage caused indirectly by viral proteins through increased oxidative 
stress in a setting of impaired anti-oxidant defenses. We hoped to attain 
additional knowledge on the pathogenesis of HAD, studied in a Sub-Saharan 
African population. Information which might lead to new forms of treatment, 
earlier diagnoses and possibly even measures to prevent the advent of HAD. 
We investigated possible relationships between systemic inflammation, systemic 
oxidative stress, peripheral anti-oxidant defenses, inflammation in the brain and the 
APOE genotype and HIV-associated cognitive impairment. We measured the 
cytokines, TNF-a, IL-113 and TGF-I3, in the peripheral blood as markers of systemic 
inflammation. We studied serum levels of conjugate dienes (CD), lipid 
hydoperoxides (LOOH) and Thiobarbituric Reactive Substances (TBARS) to assess 
systemic oxidative stress. The Oxygen Radical Absorbance Capacity (ORAC) 
measured total anti-oxidant capacity. Magnetic resonance spectroscopy peaks of 
N-acetyl aspartate (NAA) and myo-inositol (MI), using chemical shift imaging (CSI) 











and inflammation in the brain. We investigated the role of the APOE E4 allele in 
inflammation and HIV-associated cognitive impairment. 
We formulated the following hypotheses regarding the associations of systemic 
inflammatory markers, markers of oxidative stress, markers of inflammation in 
the brain on MRS and the APOE E4 allele with HIV-associated cognitive 
impairment based on evidence in current literature. The rationale of these 
hypotheses will be addressed in the relevant chapters. 
1.6.1 Raised inflammatory markers in the peripheral blood are associated with 
cognitive impairment in HIV-infected patients. 
1.6.2 Inflammatory markers in the peripheral blood relate to markers of 
oxidative stress in the peripheral blood of HIV-infected patients with 
cognitive impairment. Higher levels of inflammatory markers are 
associated with higher levels of markers of oxidative stress. 
1.6.3 Inflammatory markers in the peripheral blood relates to inflammatory 
markers on MRS in HIV-infected patients with cognitive impairment. 
Higher levels of inflammatory markers are associated with higher levels 
of inflammation markers on MRS. 
1.6.4 Raised markers of oxidative stress in the peripheral blood are associated 
with greater cognitive impairment in HIV-infected patients. 
1.6.5 Raised markers of oxidative stress in the peripheral blood are associated 
with raised levels of inflammatory markers on MRS in HIV infected 











1.6.6 Anti-oxidant defenses are inversely related to markers of oxidative 
damage in participants. 
1.6.7 Anti-oxidant defenses are lower in HIV-infected patients with cognitive 
impairment. 
1.6.8 Levels of anti-oxidant defenses are inversely related to markers of 
inflammation on MRS in the eNS. 
1.6.9 Higher levels of inflammatory markers on MRS are associated with 
cognitive impairment in HIV-infected patients. 
1.6.10 The APOE E4 allele is associated with greater cognitive impairment 
in HIV-infected patients in a dose-dependent manner. 
1.6.11 The APOE E4 allele is associated with higher levels of inflammatory 
markers in HIV-infected patients in a dose-dependent manner. 
1.6.12 The APOE E4 allele is associated with higher levels of markers of anti-
oxidant stress in HIV-infected patients in a dose-dependent manner. 
1.6.13 The APOE E4 allele is associated with increased levels of inflammatory 











1.6.14 Low CD4+ count is associated with greater cognitive impairment in HIV-
infected patients. 
1.6.15 Low hemoglobin values are associated with greater cognitive impairment 












2.1 Recruitment of participants 
We performed a cross-sectional study on HIV-infected participants and HIV 
negative controls between the ages of 18 and 35 years. We recruited 35 HIV 
infected participants and 10 controls. Both participants and controls were 
recruited from the same population. Recruitment took place at the Voluntary 
Counselling and Testing services of three peripheral clinics, namely Khayelitsha 
Site C Clinic, Mitchell's Plain Clinic and the Woodstock Community Clinics, 
Western Cape, South Africa. The participants were predominantly from a lower 
socio-economic class, consisting of unskilled manual workers, domestic workers 
or they were unemployed. They had a minimum of six years of education. All 
participants were HAART naive on recruitment and investigations were 
completed prior to initiation of HAART. 
Participants were provided with information regarding the study. what 
participation involved and the extent of testing procedures. The participants gave 
written informed consent after counselling. Specific counselling for blood 
sampling and imaging was conducted and informed consent for these 
procedures taken on separate forms. Participants were booked for a neuro-
cognitive assessment at the Department of Psychiatry, Groote Schuur Hospital, 
Cape Town, South Africa. 
The exclusion criteria included: 
.. Presence of an uncontrolled medical condition, e.g. poorly controlled 
diabetes, epilepsy with ongoing seizures, active tuberculosis requiring 











excluded with a detailed medical history performed as part of the initial 
screening of participants. 
• Presence of an identified central nervous system neurological condition, such 
as lymphoma, untreated neurosyphilis or cryptococcal infection were 
excluded with detailed questioning of relevant symptoms during the medical 
questionnaire and syphilis screening on blood. The absence of gross 
pathology was confirmed on structural magnetic resonance imaging (MRI), 
which was performed at the same time as the MRS. 
• Participants who have abused alcohol or psycho-active substances within the 
preceding month. 
• Participants who in the investigator's opinion have a neurocognitive disorder 
NOT primarily due to HIV infection. 
2.2 The neuropsychological battery 
We performed a battery of neuropsychological tests on each participant, focusing 
on the sUb-cortical symptom complex associated with HAD (McArthur, 2005). 
Psychomotor speed, memory and executive function are preferentially affected 
on the neuropsychological examination of patients with HAD (Nath, 2008). Motor 
involvement result in gait disturbances with ataxia, bradykinesia, spasticity and 
loss of manual dexterity. Agitation and apathy are prevalent in HAD but 
psychiatric symptoms are diverse and include mania and psychosis (Boisse, 
2008; McArthur, 2005; Power, 2009; Nath, 2008). The home languages of the 
participants included Xhosa, English and Afrikaans. However, if the participants 
were fluent in English, the neuropsychological battery was performed in English. 
If the participants were not fluent in English, testing was performed in their 











The following domains formed part of the cognitive assessment: 
.. verbal/language 
.. attention/working memory 
.. abstract thinking 
.. memory (learning, recall) 
.. speed of information processing 
.. sensory-perceptual 
.. motor skills 
2.3 Summary of neuropsychological tools 











TABLE 3: Neuropsychological Assessment Dementia Screening Tests 
International HIV dementia scale Screening tool for HIV- Validated for use in 
(IHDS) associated dementia developing countries 
(Sacktor, N. 2005; Boisse, 2008; 
Power, 2009) 
Mini Mental State Examination Screening tool for cognitive 
(MMSE) impairment 
(Folstein, 1975) 
a) Functional Assessment Tools 
HIV Neurobehavioral Research Assessment of general 
Centre (HNRC) Activities of Daily functioning 
Living (ADL) 
The Patient's Assessment of Own Self-assessment tool to 
Functioning (PAOF) assess general functioning 
Neuropsychiatric Inventory (NPI) Screening for 
psychopathology 
(Cummings, 1994) 
A quality of life instrument Self reported tool on quality 
of life 
(Antinori, 2007) 
b) Motor Speed And Coordination 
Grooved Pegboard Testing manual dexterity and 25 pegs are rapidly 
co-ordination for the inserted in a slotted 
(non-dominant) dominant and non-dominant form board with each 
hand and motor speed hand individually 
Finger tapping Motor speed and motor The test is performed 
control bilaterally; five 
(non-dominant) consecutive 10 second 
trials of repetitions are 
timed 
Timed gait Motor speed Walking speed over 











TABLE 3: Neuropsychological Assessment Dementia Screening Tests 
c) Memory Learning and retrieval are impaired in HAD 
Working, semantic and long term memory are 
preserved 
The Hopkins Verbal Learning Test HVL T is a brief assessment Based on recognition 
of verbal learning and and recall of various 
Recall (HVL T) memory figures 
The Brief Visuospatial Memory Test Visuospatial and recall ability Reproduction of the 
features and spatial 
Recall placement of two 
dimensional geometric 
figures 
The Rey Osterreith Complex Figure Various cognitive domains Copying and drawing a 
are involved including complex figure from 
Copy visiospatial, attention, memory 
planning and working 
(Corwin, 1993) memory 
Wechsler Memory Scale Most sensitive tool in early Memorizing of stories 
HAD 
(Wechsler, 1997) 
The Mental Alternation Test Sequencing and category Patients count up to 20, 
switching then recite the alphabet, 
thereafter they must 
alternate numbers and 
letters chronologically in 











TABLE 3: Neuropsychological Assessment Dementia Screening Tests 
d) Psychomotor speed and Attention 
Trail-Making Visual attention, task A connect-the-dot task 
switching and mental 
Trail Making A : (Reitan, 1958) flexibility 
consecutive numbers 
Digit Symbol Coding Assessing processing speed Consist of digit-symbol 
pairs. The digit is then 
(McArthur, 2005; Grant, 2008) Close correlation with global given and the patient 
impairment (Bottiggi, 2007) must write the symbol 
as fast as possible 
Color Trails 1 &2 Visual attention, task The test does not 
switching and mental require knowledge of 
(D'Elia, 1996) flexibility the alphabet, using 
colors instead of letters. 
Recommended in subjects Trails 1 involves 
who speak English as connecting consecutive 
second language numbers, Trail 2 has 
two color number pairs, 
the colors must be 
alternated during 













TABLE 3: Neuropsychological Assessment Dementia Screening Tests 
e) Executive functions abstract reasoning, planning and decision making 
The Stroop Colour Word Test Executive functions, The Stroop effect is obtained 
assessing speed of by printing names of colours 
(Stroop, 1953) processing, selective in conflicting colours. 
attention and cognitive Reading speed slows when 
flexibility compared to reading of 
names printed in black 
The Wisconsin Card-Sorting Test Executive functions, The test employ shapes, 
especially frontal lobe colours and quantities, with 
(Nelson, 1976) functioning, including change in instruction to 
attention, set-shifting, assess the ability to 
modulating impulsive recognize sets 
responses and goal 
directed action 
Trail-Making Visual attention, task A connect-the-dot task 
switching and mental 
Trail Making B: alternating ( Grant, 2008) flexibility 
numbers and letters, 
assessing task switching 
abilities. 
f) Verbal Language Skills Fluency deteriorates with impaired word generation 
Verbal fluency tests Language especially Naming tests of animals and 
fluency with impaired fruit or vegetables 
.. Category Fluency Animals spontaneous generation 




g) Cognitive Functioning and Intellectual Ability 
Wechsler Abbreviated Scale of Quick tool to evaluate We applied the four subsets 
Intelligence (WASI) cognitive functioning and of vocabulary, block design, 
intellectual ability similarities and matrix 











2.4 Neuropsychiatric Score (NP Score) 
No validated normative data are available for our population. Z-scores were 
calculated from control data and used to calculate the degree of impairment. 
Scoring was based on the updated American Academy of Neurology Criteria 
(Joska, 2010; Antinori, 2007). 
TABLE 4: Neuropsychiatric Score (NP Score) 
NP score Staging Requirement 
2 Moderate to severe cognitive Participants with a performance of two standard 
impairment (HAD) deviations below the mean in two cognitive 
domains 
1 Mild cognitive impairment Participants whose performance scored at least 
one standard deviation below the mean in two 
domains of cognitive function 
0 No cognitive impairment Participants with less than one standard deviation 
from the mean across all domains tested 
(Joska, 2010) 
2.5 Composite score 
Participants were classified into three groups using data obtained from the self 
reported tests, neuromedical examination and neuropsychological battery. A 
neurological raw score was compiled interpreting neurological symptoms on a 
semi-quantitative scale. 
The Patient's Assessment of Own Functioning Index (PAOFI) was used to score 
functional impairment. Scores were rated on a scale from 0 to 2 to calculate a 















Immunodeficiency Syndrome (AIDS) Dementia (NEAD) Consortium study with 
the Memorial Sloan-Kettering (MSK) scale (Marder, 2003). The 
neuropsychological test battery and the composite scoring system were 
developed in collaboration with Dr John Joska and the team at the 
Neuropsychology Unit at the Department of Psychiatry (Joska, 2010). 
2.6 The physical examination 
The physical evaluation included a general physical examination and a 
neurological examination, which focused on the evaluation of gross and fine 
motor skills. 
2.7 Blood specimens 
A total volume of 30 millilitres of blood was obtained for performance of blood 
tests. 
2.7.1 General markers 
A general blood evaluation, including full blood count, HIV status, CD4 count, 
viral load and highly sensitive C-reactive protein (CRP), was obtained. 
l 2.7.2 Method: Inflammatory markers 
Obtained specimens for inflammatory markers and oxidative stress markers were 











freezer for later analyses. Inflammation markers included IL-1, TNF- a and TGF-
{3. Blood samples for inflammatory markers were processed at the immunology 
laboratory of the medicine department, University of Cape Town (UCT). 
2.7.3. Methods: Oxidative Stress Markers 
Oxidative stress markers included thiobarbituric acid reactive substances 
(TBARS). conjugated dienes (CD), lipid hydro peroxides and anti-oxidant or total 
reductive defence capacity assessed with the Oxygen Radical Absorbance 
Capacity (ORAC) test. 
Thiobarbituric acid reactive substances (TBARS). conjugated dienes (CD) and 
lipid hydro peroxides (LOOH) were used to assess lipid peroxidation and the 
production of 4-hydoxynonenal (4-HNE) associated with oxidative stress and the 
Oxygen Radical Absorbance Capacity (ORAC) test was used to assess total anti-
oxidative potential (Turchan, 2003). Assays for markers of oxidative stress were 
performed at the lipid Laboratory, UCT. 
2.8 Magnetic Resonance Spectroscopy (MRS) 
A separate attendance was scheduled to perform imaging studies on 
participants. Imaging was performed at the Cross University Brain Imaging 
Centre (CUBIC) at Stellenbosch University Medical School in collaboration with 
the medical imaging unit at UCT. Transport for participants was arranged to the 











Magnetic Resonance Spectroscopy (MRS) was used as a non-invasive method 
for the assessment of metabolite levels in the brain and served as a measure of 
inflammation in the brain. In view of the importance of sub cortical involvement in 
the pathology of HIV-associated cognitive impairment, the voxel was placed to 
include the lentiform nucleus. MRS-related inflammatory markers were compared 
to peripheral measures of inflammation and oxidative stress in the blood. 
Metabolites were compared between groups with different stages of cognitive 
impairment, including HIV-infected subjects with cognitive impairment, HIV-
infected subjects without cognitive impairment and HIV-negative control groups. 
This enabled us to assess the relationship of systemic inflammation, markers of 
inflammation in the brain on MRS and HIV-related cognitive impairment. 
The following metabolites were analyzed using creatine as reference: 
• N-acetyl aspartate: Creatine 
• Myo-inositol: Creatine 
• Choline: Creatine 
• Lactate: Creatine 
• (Lipid+Lactate): Creatine 
N-acetyl aspartate was used as marker of mature neurons, myo-inositol as 
marker of glial proliferation and lactate as marker of anaerobic glycolysis. 
MRS metabolite values were also related to the APOE genotype to investigate 













2.9 APOE genotyping 
We assessed the relationship between the APOE genotype and inflammation, 
oxidative stress and metabolites of neuronal injury on spectroscopy respectively, 
to evaluate the role of APOE genotype in the development of HIV-associated 
cognitive impairment. 
Blood samples of the subjects and controls were collected after informed 
consent. APOE genotyping on the samples was performed at the Department of 
Chemical Pathology (UCT Medical School). APOE genotyping was also 
performed on cord blood collected from 300 newborn babies to acquire a 
population allelic frequency for APOE E4 in the same population. 
2.10 Statistical Analyses 
The statistician at The Medicine Department of UCT was consulted to assist with 
statistical analyses. Analyses were performed with parametric (chi-square, 
analysis of variance (ANOVA), Tukeys HSD (Honestly Significantly Differences» 
and non-parametric tests (Wilcoxon W.; Kruskal-Wallis Rank test, Mann Whitney 
U) in two-sided tests and multiple linear regression procedures. Statistical 
significance was declared at the 5% level. Analyses were performed using 

















The study is a collaboration between Assoc Prof Marc Combrinck from the 
Neurology Division of the Department of Medicine, and Dr John Joska, from the 
Department of Psychiatry, and has been approved by the Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town 
(REC 263/2007). The genotyping of the 300 newborn babies for the 
determination of the population allelic frequency was done with ethical approval 
of the Research Ethics Committee of the Faculty of Health Sciences of the 
University of Cape Town (REC 093/2002) on cord blood previously collected by 
Prof Henderson from the Department of Chemical Pathology, UCT, as part of an 
international collaborative project. The study was conducted according to the 
ethical guidelines and principles of the International Declaration of Helsinki, 
South African Guidelines for Good Clinical Practice and the Medical Research 












3.1 HIV entry into the Central Nervous System 
The blood brain barrier (BBB) is selectively permeable due to tight junctions 
which adhere endothelial cells and astrocytes in close opposition. Upregulation 
of cytokines and nitric oxide (NO) during HIV infection increases the permeability 
of the BBB with an increase in traversing of immune factors (Hult, 2008; Ellis, 
2009). Several factors accelerate entry into the CNS, impairment of tight 
junctions lead to increased penetration of HIV through the blood brain barrier, 
TNF-a mediates BBB breakdown through increased expression of adhesion 
molecules, and an increase in production of chemokines augments infiltration of 
HIV-infected monocytes and macro phages into the brain (Kedzierska, 2004). 
HIV utilizes several routes to enter the CNS across the impaired blood brain 
barrier. HIV may infect endothelial cells with subsequent invasion of the 
parenchyma. A paracellular route could provide direct entry to HIV without 
intermediate cell involvement. HIV may cross the blood brain barrier 
intracellularly carried in monocytes, macro phages and clusters of differentiation 
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3.2 Inflammation: the indirect mechanism 
HIV-1 forms part of the lentivirus subfamily of the retroviruses and shows 
neurotropism. Macrophage tropic (M-tropic) viruses infect monocytes, microglia 
and macrophages via the CD4 and chemokine co-receptor S (CCRS) receptors. 
Lymphocytes and astrocytes are infected via the CXC-chemokine receptor 4 
(CXCR4) co-receptor. T-tropic strains utilize the CXCR4 co-receptor, infecting 
mainly CD4+ T-cells and other T-cell lines. 
During viral entry the gp120 envelope protein binds to the CD4+ molecule. 
Gp120 undergoes conformational changes, exposing the chemokine receptor 
binding domain of chemokine co-receptors for binding. Conformational changes 
in gp41 mediate fusion of the virion lipid membrane and the cell membrane, 
followed by entry of the virion into the cytoplasm (Kedzierska, 2002). Neurons, 
oligodendrocytes and epithelial cells are not productively infected by HIV 
(Kedzierska, 2002) and with limited evidence of the intracellular presence of HIV 
in neurons, direct infection of neurons remains controversial (Boisse, 2008; 
Ghafouri, 2006). Viral replication in astrocytes is highly restricted (Anderson, 
2002). HIV mRNA is efficiently transcribed, but translation into structural HIV 
proteins is incomplete, with production of only HIV associated proteins (Gorry, 
2003). Replication-competent viral genome persists, creating a viral reservoir. 
Astrocytes act as a sanctuary site against viral eradication, harbouring HIV 
genome which maintains reproductive capabilities. 
HIV production occurs predominantly in macrophages. The predominant 
underlying mechanism in the pathogenesis of HAD is neuro-inflammation 











result of cytokine release from microglia, macrophages and astrocytes, with 
neurodegeneration and cognitive impairment secondary to inflammation. 
Proliferation of microglia, macro phages and astrocytes associated with 
inflammation is a pathognomonic feature of HIV-associated cognitive impairment 
and inflammatory markers may possibly have value as markers of 
neurodegeneration in HAD. 
Tissue macro phages and macro phages derived from monocytes (MOM), the 
blood derivatives of monocytes, are infected by HIV. Perivascular macrophages 
are one of the major lineages affected by HIV (Williams, 2002; Anderson, 2002) 
and meningeal macro phages which are rapidly replenished by bone marrow 
derived monocyte/macrophages provide a route for early HIV invasion (Williams, 
2002). Once monocytes enter the brain they differentiate into macrophages and 
form multinucleated giant cells (MNGC). Multinucleated giant cells (MNGC) are 
rare in the CNS. In the presence of a foreign body or an intra-cellular pathogen 
which cannot be removed, as seen in retroviral infections, macrophages fuse and 
form MNGC. MNGC are the histopathological correlate of HAD and are 
pathognomonic of HIV-associated encephalitis (Williams, 2002). Further 
histopathological features of HIV-associated encephalitis include astrogliosis, 
microglia nodules, dentritic and axonal damage, and neuronal loss (Anderson, 
2002; Kedzierska, 2004). The degree of monocyte infiltration and macrophage 
activation correlates with the degree of cognitive impairment (Boisse, 2008). 
Macrophages can produce HIV for months without cytopathic effects 
(Kedzierska, 2002). Macrophages utilize the endosome and exosome system for 
production of HIV rather than vesicles budding from the plasma membrane. The 
latter process would result in cell death. This longevity of macro phages creates 











potential of brain macrophages poses an additional infection threat (Anderson, 
2002). 
Multinucleated giant cells and microglial nodules release pro-inflammatory 
mediators. Microglia are activated by pro-inflammatory cytokines with expression 
of additional pro-inflammatory cytokines, including IL-113 and TNF-a, chemokines, 
viral proteins and ROS (including NO, produced by iNOS) and superoxide, 
produced by NAPDH oxidase (Kedzierska, 2002; Saha, 2003; Dheen, 2007). 
Microglia may have cytotoxic effects through direct contact with neurons or 
indirectly via these neurotoxic mediators. 
Neurodegeneration is promoted by inflammatory mediators including tumour 
necrosis factor-alpha (TNF-a) and interleukin-1 beta (IL-113). Cytokines mediate 
additional cytokine release through paracrine stimulation of macrophages and 
astrocytes with amplification of the inflammatory response. Cytokines augment 
the accumUlation of glutamate in the extracellular space. The excess in 
inflammatory mediators impairs reuptake of glutamate due to suppression of the 
excitatory amino acid transporters with a resultant increase in extracellular 
glutamate, excitotoxicity and cell death (Alison, 2007). 
Astrocytes provide support to both neurons and glia and are involved in the 
maintenance of blood brain barrier integrity. Astocytes regulate glutamate 
metabolism (Gorry, 2003) and modulate the immune response by presenting 
antigens to T-cells with stimulation of T-cell responses (Minagar, 2002). 
Astrocytosis is a defining feature of HIV encephalitis, occurring early after the 
initial infection with proliferation of astrocytes and astrocyte apoptosis mediated 











inhibits astrocyte proliferation, but with an increase in size of astrocytes, which is 
a feature of astrocytosis. Astrocytes promote neurotoxicity through release of 
viral particles, production of cytokines and impairment of glutamate metabolism 
(Anthony, 2008). Astrocytes play an important role in the inflammatory process 
through the creation of a self-propagating cycle of cytokine production. 
Paracrine immune activation by macrophages induces astrocyte apoptosis with 
secretion of cytokines. Astrocyte apoptosis cause a positive feedback with 
increased activation of macro phages and cytokine release. 
Astrocytes play an important role in increased excitotoxicity. Glutamine released 
from astrocytes is taken up by neurons at the nerve terminals and converted to 
glutamate by glutaminase. Cytokines impair glutamate metabolism in astrocytes 
with an increased release and decreased uptake of glutamate (Hult, 2008) 
(Anderson, 2002). Excessive extracellular glutamate acts on post-synaptic 
glutamatergic receptors, including NMDA and non-NMDA receptors, leading to 
excitotoxicity and neuronal apoptosis (Alison, 2007). 
Mechanisms involved in neuronal death include both apoptosis and necrosis 
(Boisse, 2008; Hult, 2008). Apoptotic cell death is initiated via caspases in milder 
insults (Brabers, 2006). Apoptosis, also called programmed cell death, involves 
cell shrinkage, membrane blebbing, nuclear pyknosis and early chromatin 
condensation. Necrosis takes place in severe insults with loss of ionic 
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3.3 The role of viral proteins in HAD 
Viral proteins cause neurodegeneration in HAD through direct and indirect 
mechanisms (Minghetti, 2004). Direct neuronal toxicity is mediated through 
effects on neurons and indirect toxicity occurs through release of inflammatory 
mediators (Power, 2009). 
Indirect neurotoxicity is mediated by activation of inflammatory cytokines, 
feedback activation of viral proteins and activation of the innate immune system 
(Boisse, 2008). Tat impairs the BBB through interaction with the tight junction 
proteins of endothelial cells with a resultant increased influx of inflammatory cells. 
Gp120 utilizes chemokine receptors to facilitate inflammatory mediator entry 
across the blood brain barrier, increasing neurotoxicity (Kaul, 1999). 
Tat mediates production of pro-inflammatory cytokines including Il-1~, Il-6 and 
TNF-a (Buscemi, 2007) (Ghafouri, 2006; Hult, 2008). Tat also mediates cytokine 
release by down regulation of adenosine 3', 5'-cyclic mono phosphate (cAMP) 
with impaired suppression of cytokine production (Williams, R. 2009). The 
consequent release of cytokines accelerates HIV infection. 
Tat and gp120 induce excitotoxicity through stimulation of the NMDA receptor by 
glutamate and l-cysteine, with increased intracellular calcium and NO levels, 
excitotoxicity and caspase-induced apoptosis (Ghafouri, 2006). Excitotoxicity is 
produced synergistically with other pro-inflammatory mediators and viral proteins. 
(Buscemi, 2007; Mayne, 2000; Kaneko, 1997). TNF-a exposure to HIV antigens 
also contribute to activation of astrocytes with an increased rate of cytokine 











Tat promotes HIV entry into cells through increased calcium influx (Minghetti, 
2004). TNF-a may induce HIV replication in macrophages through induction of a 
transcriptional factor (Chen, 1997). Gp120 impairs glutamate metabolism by 
inhibiting uptake of glutamate through release of NO and arachidonic acid from 
astrocytes (Hult, 2008) (Minagar, 2002). Gp120 also up-regulates release of L-
cysteine by macro phages and microglia through TNF-a and IL-1J3 (Brabers, 
2006). 
3.4 Inflammatory markers 
3.4.1 Tumour Necrosis Factor alpha (TNF-a) 
TNF-a plays an integral part in the pathogenesis of HAD. TNF-a is produced as 
a 26 kilodalton (kDa) membrane-bound polypeptide precursor which is cleaved 
by TNF-a converting enzyme to a 17 kDa bioactive subunit. 
HIV dementia is associated with an increase in plasma TNF-a and levels 
correlate with severity and progression of disease (Sevigny, 2004). TNF-a 
increase the permeability of the blood brain barrier and opens a paracellular 
pathway for HIV entry (Saha, 2003). Increased production of adhesion 
molecules and chemokines by TNF-a facilitates entry of HIV infected monocytes 
and macrophages through the impaired blood brain barrier (Brabers, 2006). 
Activated macrophages secrete IL-1 J3 and TNF-a, with markedly higher levels of 
TNF-a in HAD (Saha, 2003). TNF-a shows paracrine activity through increased 
release of pro-inflammatory mediators by activated macrophages, microglia and 
astrocytes (Brabers, 2006) and TNF-a mediates cell death synergistically with 











TNF-a mediates neurotoxicity through excitotoxicity. Autocrine effects of TNF-a 
result in amplification of glutamate release by astrocytes in the presence of 
chemokines. TNF-a, in association with IL-113, upregulates iNOS expression with 
increased NO production and glutamate release (Saha, 2003). TNF-a inhibits 
uptake of glutamate by astrocytes (Brabers, 2006). TNF-a increases production 
of L-cysteine, an excitatory amino acid and precursor of glutamate and 
extracellular glutamate further inhibits L-cysteine uptake (Anderson, 2002). 
These increases in glutamate mediate cell death and neurodegeneration 
associated with HAD. 
TNF-a mediates neurotoxicity through several other neurotoxins. TNF-a and IL-
113 are associated with an increase in sphingomyelin and ceramide production 
causing oxidative stress through ROS production. Platelet activating factor 
(PAF) is stimulated by TNF-a, leading to increased microglia activity with 
phagocytosis, chemotaxis, calcium influx, and arachidonic acid release and 
superoxide anion production. PAF reciprocally induces production of TNF-a 
(Brabers, 2006). Genetic factors may influence the TNF-a levels in HAD. The 
TNF-a-308-A allele has a much higher frequency in HAD and is associated with 
increased TNF-a expression and increased cytokine production (Saha, 2003). 
TNF-a causes direct neurotoxicity through caspase activation after binding with 
TNF-a receptor on neurons (Saha, 2003; Chaparro-Huerta, 2002). TNF-a is the 
predominant mediator of the inflammatory cascade associated with 
neurodegeneration and HIV associated cognitive impairment. 
However, in addition to the neurotoxic effects described, TNF-a also has a role in 
neuroprotection and may display anti-inflammatory properties. Neuroprotection 
was suggested through studies showing an attenuated rise of calcium in neurons 











receptors and increases outward potassium flow with attenuated excitotoxicity. 
Upregulation of protective chemokines by TNF-a results in decreased 
neurotoxicity (Saha, 2003) and TNF-a may induce anti-apoptotic features. 
(Minagar, 2002). TNF-a plays a neuroprotective role in beta-amyloid toxicity 
(Brabers, 2006) which may be of importance in HIV-associated cognitive 
impairment. 
3.4.2 Interleukin-1 beta (ll-113) 
IL-1 ~ is produced by macrophages and causes macrophage activation (Williams, 
2002). IL-1 ~ release is regulated by caspase-1, the IL-1 ~ converting enzyme 
(Brabers, 2006). 
HIV dementia is associated with increased plasma levels of IL-1~, iNOS, TNF-a 
and caspase-1 compared to non-demented controls (Brabers, 2006). IL-1 ~ 
mediates viral entry through impairment of the BBB and enhanced expression of 
adhesion molecules leading to an increase in monocyte infiltration. IL-1 ~ 
activates astrocytes and, in association with TNF-a, induces iNOS expression in 
astrocytes with NO production (Brabers, 2006). IL-1 ~ induces excitotoxicity 
through calcium i flux secondary to stimulation of the NMDA-receptor by 
glutamate and L-cysteine. IL-1 ~ is involved in oxidative stress through ceramide 
production leading to ROS-mediated neurotoxicity and apoptosis (Brabers, 
2006). 
Viral proteins are involved in the cytotoxic expression of IL-1~. Tat mediates NO 
production through caspase-1 activation of IL 1-beta (Brabers, 2006) and Gp120 











neurodegeneration by these mechanisms. An increase in IL-1 ~ levels relate to 
neuronal loss associated with HAD. 
As with TNF-a, IL-1~ fulfills a dual role. The aforementioned mechanisms are 
involved in neurodegeneration, but also playa role in neuroprotection. IL-1 ~ 
protects through nerve growth factor, and in the presence of IL-1-induced NO a 
decrease in viral replication is seen (Brabers, 2006). 
3.4.3 Transforming Growth Factor beta (TGF-f3) 
TGF beta shows predominantly neuroprotective mechanisms, but is also 
associated with proinflammatory mechanisms involved in neurodegeneration 
(Hurwitz, 1995). The inflammatory response induced by microglia impairs 
neurogenesis. TGF-beta acts as an anti-inflammatory cytokine (Dheen, 2007) to 
offer neuroprotection. TGF beta is associated with suppressed macrophage and 
T- and B-cell function and may ameliorate HIV infection. Increased TGF beta 
levels in the CSF were found to be inversely related to CSF viral load and 
disease severity (Alfano, 2005; Perella, 2003). 
TGF beta has been associated with detrimental effects in HAD. The following 
mechanisms are involved in TGF beta associated neurodegeneration: TGF beta 
is associated with suppression of HIV early on in infection, but stimulates HIV 
replication later in the disease. TGF beta influences chemo-attraction of 
inflammatory cells through upregulation of TNF-a-induced chemokine expression 
(Hurwitz, 1995). Paracrine effects of IL-1~ result in increased levels of TGF beta 
(Chao, 1994; Wahl, 1991). TGF beta antagonizes or augments the action of IL-
1 ~ depending on the stage of infection (Vitcovic, 1997). TGF beta production is 











Apoptotic cell death in the central nervous system is not associated with a typical 
inflammatory response. An anti-inflammatory cytokine profile with increased 
levels of TGF beta is present to counter act a detrimental pro-inflammatory 
response. This initial protective anti-inflammatory response may evolve into a 
detrimental pro-inflammatory response during excessive inflammatory stimuli, as 
seen in experiments of induced systemic infection (Perry, 2002; Perry, 2004). 
The role of TGF beta, whether neuroprotective or neurodegenerative, needs to 
be ascertained by further research. 
3.5 Systemic Infection 
The release of pro-inflammatory cytokines during systemic infection is suggested 
as a mechanism of increased neurodegeneration. Systemic infection is 
associated with an increase in BBB permeability, increased entry of peripheral 
immune cells and neuronal toxicity (Solerte, 2000). Studies suggested that pro-
inflammatory cytokines measured in the serum are increased in dementia. 
Systemic markers of inflammation may relate to inflammation in the brain. Thus 
the measurement of thes  systemic markers in the peripheral blood may be 
useful in the monitoring cognitive impairment in the peripheral blood. 
In previous studies systemic inflammation relates to markers of inflammation in 
the brain. Lipopolysaccharide (LPS) induced a systemic inflammatory response 
with an increase in the serum levels of IL-1~, TNF-a and IFN-y. Elevations of 
cytokines in HIV infection resembled the findings in systemic infection, 
suggesting a shared inflammatory mechanism (Munno, 1992). Further studies 
found increased IL-1 ~ levels in the brain after induction of systemic inflammation 











infection is believed to gain entry to the central nervous system through the 
impaired blood brain barrier. Systemic cytokines induce an increase in 
permeability of the BBB through altered tight junctions, creating a paracellular 
entrance. The vagus nerve serves as another pathway of entry to the brain 
during systemic inflammation via neuro-humeral signaling from the periphery. 
Alzheimer's disease and HIV dementia share a common pathogenic mechanism 
through the presence of beta-amyloid. Based on the shared pathogenesis of 
beta amyloidosis, systemic infection in HIV may contribute to the development of 
HIV dementia in a similar way to the increased cognitive impairment during 
systemic infection in Alzheimer's disease. 
Neuroinflammation with excess cytokine production, including IL-1, TNF-a and 
interferon-gamma, leads to amyloid deposition. TNF-a stimulates amyloid 
production directly through the beta site of the amyloid precursor protein (APP) 
cleaving enzyme 1 (BACE1). Oxidative stress mediates amyloid beta deposition 
and an increased amyloid beta load in the brain. The presence of amyloid beta 
increases HIV infection rate through increased HIV cell fusion synergistically with 
APOE E4 (Mahley, 2009). 
Chronic infections in the elderly lead to increased inflammatory and oxidative 
stress responses which could predispose subjects to Alzheimer's disease (AD). 
Systemic infection leads to increased inflammatory responses and associated 
neurodegeneration in the brain. Prior priming of glial cells in chronic 
neurodegenerative disease results in the transformation of the anti-inflammatory 
state of microglia and macro phages in the brain to a pro-inflammatory cytokine 
profile in the presence of systemic infection (Teeling, 2009). Thus, systemic 











inflammation and associated neurodegeneration in the brain with cognitive 
decline (Honjo, 2009). 
During systemic infection in the elderly cognitive impairment worsened and 
remained impaired for a prolonged period after the systemic infection resolved 
(Holmes, 2003). Previous studies found a significant rise in systemic TNF-a 
(Sevigny, 2004; Paganelli, 2002; Xu, 2009) and IL-1 ~ in AD patients, suggesting 
increased cytokine representation in the periphery (Crabb Breen, 2002). 
Systemic levels of TNF-a were associated with a prolonged detrimental effect on 
cognitive function (Holmes, 2009). A relationship was found between increased 
IL-1~ in the serum and cognitive decline in patients with Alzheimer's dementia. 
Elevated levels of IL-1~ in the brain after systemic inflammation and elevated 
levels of IL-1 ~ in the peripheral blood, associated with cognitive decline, could 
imply a shared pathogenic mechanism. The increase in IL-1 ~ levels were 
associated with memory impairment due to impaired synaptic functioning (Malek-
Ahmadi, 1998; Teunissen, 2002; Solfrizzi, 2006). 
Although we focus on a causal relationship between systemic inflammation and 
brain inflammation in HAD, studies have found changes in systemic cytokines 
reliant on central immune responses. Mice injected with amyloid into the brain 
showed not only an increase in IL-6 in the brain but also in the plasma levels of 
IL-6. This supports a complicated interrelationship between systemic and central 
immune responses of which the mechanism is still incompletely comprehended 
(Song, 2001). 
3.6 Hypotheses: Inflammatory Markers 
Abovementioned literature supports inflammation as an integral part of the 











markers of inflammation in the peripheral blood and markers of oxidative stress 
in the peripheral blood will relate in patients with HIV-associated cognitive 
impairment. We further hypothesized that both the inflammatory markers in the 
peripheral blood, and the markers of oxidative stress in the peripheral blood will 
relate to inflammation in the brain or MRS in HIV-infected patients with cognitive 
impairment. We also hypothesized that the APOE E4 allele will correlate with 
markers of inflammation in the peripheral blood and the brain, and with HAD. 
3.7 Methods: Inflammatory Markers 
3.7.1 TNF-a Method 
For quantitative measurement of TNF, we utilized the Assay Designs' human 
TNF TiterZyme® Enzyme Immunometric Assay (Catalog No. 900-099). The 
assay was performed according to the manufacturer's instruction. A monoclonal 
antibody against human TNF alpha is immobilized on a microtiter plate and used 
to bind human TNF alpha in the specimen. Streptavidin conjugated to 
Horseradish peroxidase subsequently binds to the biotinylated human TNF 
antibody. The colour generated after short incubation is read at 450nm. This 
optical density is directly proportional to the concentration of TNF present in the 
sample. 
We used the seven standards provided to calculate a standard curve. The 
standard curve obtained from these results is presented in figure 4. Previously 
collected blood samples were spun down immediately after collection and 
supernatant serum pipetted and frozen at minus 70 degrees Celsius. 100j..ll of 











3.7.2 Interleukin-1p Method 
We utilized the TiterZyme® Enzyme Immunometric Assay (EIA) Human IL-1 ~ kit 
from Assay Design Inc. (Catalog No. 900-130) with a sensitivity of less than 
1 pg/ml. The assay was performed according to the manufacturer's instruction. 
Samples were collected from participants as described (2.7, 3.7.1) and stored at 
minus 70 degrees Celsius until serum were thawed at room temperature to 
perform the assay. 
The human IL-1 ~ standards were prepared. The five standard samples, 
numbered 1 through 5, were 400, 160,64,25,6 and 10,24 pg/ml respectively, as 
provided by the manufacturer. The standard curve of our assay is presented in 
figure 4. 
The assay utilizes an antibody against human IL-1 ~ which is immobilized on a 
microtiter plate and binds with human IL-1~. A biotinylated antibody binds with 
the captured human IL-1~ on incubation. Streptavidin-horseradish peroxidase 
(HRP) solution is added and incubated to bind with the biotinylated human IL-1 ~ 
antibody. The colour generated is read at an optical density of 450nm. The 
measured optical density is directly proportional to the concentration of human 
IL-1~ in the sample. 
3.7.3 TGF-p1 Method 
We utilized TiterZyme® EIA Human TGF~-1 from Assay Design Inc. (Catalog # 
900-155). The assay was performed according to the manufacturer's instruction. 
Serum was used to perform the assay and six standards were prepared with the 
samples according to the assay specifications. The standard curve of TGF~-1 is 











The assay incorporates wells coated with monoclonal antibodies in binding 
TGF~-1 after which a polyclonal antibody binds to bounded TGF~-1. Addition of 
Streptavidin-horseradish peroxidase (HRP) conjugate and 3,3',5,5' 
tetramethylbenzidine (TMB) substrate elicit a colour response. The colour is 
read at an optical density of 450nm. The optical density provides a directly 
proportional measure of the level of TGF~-1 in the sample. 
FIGURE 4: The Standard Curves of TNF-a, IL-1 P and TGF-p 
The following graphs represent the standard curves of the TNF-a, IL-1 ~ and TGF-~1 
assays. They represent a plot of the standards provided by the manufacturer against 
the optical density readings at 450nm measured using an ELISA plate reader. 
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TABLE 5: Demographic data of participants 
Variable Distribution HIV-negative controls HIV -infected patients 
(N == normal) (n == 10) (n == 33) 
Mean Mean 
± Standard Deviation ± Standard Deviation 
Haemoglobin N N/A 11.5 ± 1.8 
Platelets N N/A 278.4 ± 75.5 
Median Median 
(Interquartile Range) (Interquartile Range) 
Age Non N 23.5 30.0 
(20.0 - 33.0) (27.0 - 32.0) 
White Cell Count Non N N/A 5.3 
(4.3 - 6.7) 
CD4 count Non N N/A 186.5 











TABLE 5: Continued 
Distribution HIV-infected HIV-infected HIV-infected 
Variable 
(N = normal) NP 0 (n = 9) NP 1 (n = 13) NP 2 (n = 12) 
Mean Mean Mean 
± Standard ± Standard ± Standard 
Deviation Deviation Deviation 
Hb N 12.8 ± 2.1 11.9 ± 1.4 11.0±1.7 
Median Median Median 
(Interquartile Range) (Interquartile Range) (Interquartile Range) 
7.0 4.9 5.0 
WCC Non N 
(3.5 - 9.7) (3.9 - 6.6) (4.5 - 6.1) 
CD4 184.0 168.0 145.5 
Non N 
count (92.0 - 314.5) (71.3 - 271.3) (86.3 - 204.8) 
29.0 31.0 31.0 
Age Non N 











TABLE 6: Descriptive data: Inflammatory Markers 
Variable Distribution H IV negative controls HIV -infected patients 
(N = normal) (n = 10) (n = 33) 
Median Median 
(Interquartile Range) (Interquartile Range) 
IL-1~ Non N 2.3 (2.0 - 4.8) 2.7 (2.1 - 3.6) 
TNFa Non N 23.7 (20.9 - 25.8) 23.8 (23.1 - 26.1) 
TGFfj Non N 511.2 (476.7 - 601.5) 481.8 (384.3 - 557.8) 
Variable Distribution HIV-infected HIV-infected HIV-infected 
(N = normal) NPO NP 1 NP2 
Median Median Median 
(Interquartile Range) (Interquartile Range) (Interquartile Range) 
IL-1B Non N 1.7 (1.3 - 2.0) 2.8 (2.1 - 3.6) 3.6 (3.1 - 5.2) 
TNFa Non N 23.2 (23.0 - 25.7) 23.4 (23.0 - 26.6) 25.2 (22.8 - 30.9) 
TGFfj Non N 504.8 446.4 428.6 











3.8 Results: Inflammatory Markers 
We found a significant correlation between IL-1 ~ levels in the peripheral blood 
and the various degrees of cognitive impairment. 
Levels of IL-1 ~ in the peripheral blood were highest in HIV-infected participants 
with severe cognitive impairment, compared to HIV-infected participants without 
cognitive impairment (Wilcoxon rank-signed test, Z-score ::: -2.816, p ::: 0.005). 
Refer to table 7. 
IL-1 ~ levels in the peripheral blood were significantly increased in HIV-infected 
participants with severe cognitive impairment compared to HIV-infected 
participants with mild cognitive impairment (Wilcoxon signed-rank test, Z-score ::: 
-2.342 p::: 0.019). See table 7. 
The correlation of IL-1 ~ levels among groups was significant in a dose-
dependent manner, with highest levels of IL-1 ~ present in HIV-participants with 
greatest cognitive impairment (Chi-square, 10.182, P ::: 0.006). Refer to table 7. 
These findings support the hypothesis which relates systemic inflammation to 
cognitive impairment in HIV-infected individuals (hypothesis 1.6.1.). 
A significant correlation between elevated levels of IL-1~, a systemic marker of 
inflammation, and decreased levels of N-acetyl aspartate, a marker of neuronal 
viability, was found when measured at an echo time of 135· milliseconds, in 
participants with HIV-associated cognitive impairment (Spearman's rank 
correlation coefficient::: -0.373, p-value 0.019, n ::: 39). See table 7. The 











MRS, supports the hypothesis relating systemic inflammation to brain 
inflammation in HAD (hypothesis 1.6.3). Previous studies found an association 
between elevated levels of IL-1j3 in the peripheral blood and cognitive impairment 
in AD (Holmes, 2003). Our study relates IL-1j3, a systemic marker of 
inflammation, to N-acetyl aspartate, a marker of neuronal integrity on MRS used 
as a marker of inflammation in the brain, in patients with HAD. This supports the 
role of systemic inflammation in the pathogenesis of HIV-associated dementia. 
Whether IL-1j3 can be used as a systemic marker of cognitive impairment in HAD 
remains to be validated in a larger study involving greater numbers of 
participants. 
An increase in TGF-j3 levels measured in the peripheral blood related to an 
increase in myo-inositol levels, measured with MRS at an echo time of 30 
milliseconds, in the brain (Spearman's rank correlation coefficient :::: 0.320, p-
value 0.050, n :::: 38), presented in table 7. Myo-inositol is a marker of glial 
proliferation on MRS. A dual role is recognized for TGF-j3, involving protective 
anti-inflammatory properties and pr -inflammatory neurotoxicity. Previous 
research in patients with Alzheimer's disease related an atypical immune 
response with increased levels of TGF-j3 in the brain to a cytokine profile 
associated with macro phages that have phagocytosed apoptotic cells (Perry, 
2002; Perry, 2004). The correlation of an increased level of TGF-j3 in the 
systemic circulation with an increased level of myo-inositol, a marker of glial 
activation in the brain, implicates TGF-j3 as a possible systemic marker of intra-
cerebral glial activation. This supports the relationship between systemic markers 
of inflammation and inflammation in the brain on MRS and HAD (hypothesis 
1.6.3). Results on TGF-j3 bordered significance and the use of TGF-j3 as 
systemic marker of inflammation in the brain in HAD needs to be validated 











We found a significant correlation between TNF-a levels in the peripheral blood 
and conjugated diene levels in the peripheral blood (Spearman's rank correlation 
coefficient = 0.363, p-value 0.018, n = 42), tabulated in table 7. These markers 
related inflammation and oxidative stress in the peripheral blood but not to 
inflammation in the brain. 
Within the group of HIV-infected participants with severe cognitive decline, levels 
of TNF-a in the peripheral blood and levels of IL-113 in the peripheral blood 
correlated (Spearman's rank correlation coefficient = 0.656, P = 0.020, n = 12), 
see table 7. This support increased systemic inflammation present in the 
peripheral blood in HIV-infected patients with severe cognitive impairment 
(hypothesis 1.6.1). Systemic inflammation has been related to cognitive 
impairment in several studies, as discussed in section 3.5 (Combrinck, 2002; 
Cunningham, 2005; Lemstra, 2007; Holmes, 2009; Honjo, 2009). Elevated 
systemic cytokines levels may be causally related to cognitive impairment in 
HAD. The latter could only be assessed in longitudinal studies as the cause must 
precede the effect. 
IL-113 levels in the peripheral blood showed an inverse correlation with lactate, a 
measure of anaerobic respiration, measured at 135 milliseconds (Spearman's 
rank correlation coefficient = -0.812, P = 0.050, n = 6), result in table 7. This, 
however, is a tentative finding because of the small numbers and borderline 
significance. 
We did not find a significant association between the APOE E4 allele and 
systemic inflammatory markers in HAD (hypothesis 1.6.11). 
In summary, markers of inflammation in the peripheral blood correlated 











in the peripheral blood also correlated with markers of oxidative stress in the 
peripheral blood and markers of inflammation in the brain measured on MRS. 











TABLE 7: Results: Inflammatory Markers 
NP 2 vs NPO NP2 vs NP1 Among NP groups N-acetyl aspartate -
135 milliseconds 
IL i-beta Wilcoxon rank- Wilcoxon signed- Chi-square, 10.182 Spearman's rank 
signed test rank test correlation coefficient 
p = 0.006 = -0.373 
Z-score = -2.816 Z-score = -2.342 
p = 0.005 P = 0.019 
p-value 0.019 
n = 39 
myo-inositol conjugated diene IL-1 !3 IL-1 !3 
30 milliseconds NP2 group 





n = 38 
TNF-a Spearman's rank Spearman's rank 
correlation correlation coefficient 






Lactate Spearman's rank 
correlation coefficient 
135 milli- = -0.812 
seconds 
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4. OXIDATIVE STRESS 
4.1 Mediators of oxidative stress: Reactive oxygen species 
Free radicals are species capable of independent existence with an unpaired 
electron. When one radical bonds with another radical, the unpaired electron is 
shared, but on bonding with a non-radical, a radical is produced. Production of 
radicals creates reactive oxygen species (ROS) leading to oxidative stress. 
Reactive nitrogen species (RNS) are produced by inducible NO synthetase 
(iNOS) in pathological states, and mitochondrial metabolism produces 
superoxide radicals through mitochondrial electron flow (Reynolds, 2007). 
Reactive oxygen species include oxygen radicals and non-radical derivatives of 
oxygen, namely superoxide (02-), hydroxyl radicals (OH-), hypochlorous acid 
(HOCI), hydrogen peroxide (H20 2) and peroxyl radicals. RNS free radicals 
include nitric oxide (NO), peroxynitrite (ONOO-) and peroxynitrous acid 
(ONOOH). Reactive oxygen species (ROS) are involved in the peroxidation of 
lipids and oxidation of proteins resulting in excitotoxicity and apoptotic cell death 
(Halliwell, 1993; Emerit, 2004). 
Oxidation-related mitochondrial damage preferentially affects areas of high 
dopamine content. Therefore subcortical areas, including the putamen, caudate 
and substantia nigra show increased vulnerability to oxidative stress. 
Oxidative stress plays an important role in neurodegeneration (Sacktor, 2004). 
In HAD the critical balance between endogenous reactive oxygen species and 
anti-oxidant defenses is impaired, resulting in oxidative stress. HIV infected 
patients are especially vulnerable to oxidative stress by age, opportunistic 











pathogens lead to activation of glial cells in response to inflammation with 
formation of an excess of endogenous reactive oxidative species (ROS). 
4.2 Excitotoxicity 
Excitotoxicity is a common pathway leading to apoptosis as a result of oxidative 
stress induced by inflammation, protein oxidation and impaired mitochondrial 
function (Emerit, 2004). Oxidative stress develops due to activation of glutamate 
receptors with an increase in intracellular calcium levels. The increase in calcium 
levels lead to excitotoxicity and apoptotic cell death. Excess extracellular 
glutamate induces excitotoxicity through overstimulation of the excitatory 
glutamate receptors. The modulatory site of the N-methyl-D-aspartate (NMDA) 
receptor is stimulated by glutamate with subsequent influx of calcium. 
Extracellular glutamate concentrations are finely regulated to prevent 
excitotoxicity. Astrocytes mediate glutamate homeostasis through the glutamate-
glutamine cycle. After uptake, glutamate is converted to glutamine through 
glutamine synthetase, requiring ATP. Subsequently, glutamine is released for 
uptake by neurons and conversion back to glutamate by glutaminase. Disruption 
of the glutamate-glutamine cycle results in an increase in extracellular glutamate 
concentrations, excessive stimUlation of excitatory receptors and an increase in 
calcium influx (Emerit, 2004). The increase in intracellular calcium levels induces 
several enzymes, including iNOS, with production of ROS and RNS via the 











4.3 HAD and oxidative stress 
In HAD several mechanisms are associated with increased excitotoxicity. HIV 
dementia is associated with dysregulation of astrocyte function due to up 
regulated cytokine release (Annunziato, 2003). Cytokines secreted by activated 
macrophages, including TNF-a and IL-1~, induce oxidative stress through 
induction of inducible nitric oxide synthetase (iNOS). iNOS initiates the 
production of nitric oxide (NO) in macro phages and astrocytes (Valcour, 2004). 
NO releases glutamate and glutamate activates the NMDA receptor with 
associated calcium influx, excitotoxicity and apoptosis (Pocernich, 2005). 
Neurons are not directly affected by HIV in HIV-associated neurodegeneration. 
Macrophages and microglia are predominantly infected with subsequent release 
of viral and non-viral products (Sacktor, 2004). Activated mononuclear 
phagocytes, including macrophages, microglia and multinucleated giant cells, 
induce oxidative stress through the release of cytokines and chemokines and 
through an increase in neurotoxins, including free radicals, glutamate and 
arachidonic acid metabolites (Emerit, 2004; Reynolds, 2007). The increase in 
cytokine release, including IL 1-~ and TNF-a, leads to neuronal death through 
excitotoxicity (Pocernich; Viviani, 2001) 
HIV-infected astrocytes, macro phages and microglia release tat and gp120. HIV 
proteins induce neuronal death through indirect oxidative damage. Gp120 and 
tat mediate oxidative stress through the release of free radicals. Tat-associated 
activation of astrocytes induces iNOS with overproduction of NO. NO in 
association with TNF-a facilitates an increase in glutamate with stimulation of the 
NMDA receptor and excitotoxicity. The increase in intracellular calcium in 











oxide and peryoxynitrite, which are neurotoxic (Pocernich, 2005; Steiner, 2006; 
Turchan, 2003; Kruman, 1998). 
4.4 lipid peroxidation 
Lipid peroxidation is mediated by free radical induced oxidative stress. 
Polyunsaturated fatty acids (PUFA) are prevalent in the brain and are especially 
vulnerable to lipid peroxidation compared to monounsaturated and saturated fatty 
acids. 
Lipid peroxidation occurs through formation of peroxyl radicals. A self-
propagating cycle of damage to lipid membranes, due to abstraction of hydrogen 
atoms from polyunsaturated fatty acids in the presence of oxygen, produces 
peroxyl radicals. Lipid peroxidation causes membrane damage with impaired 
membrane functioning, increased permeability of the membrane to calcium and 
other ions, and inactivation of receptors (Halliwell, 1993). 
4.4.1 HAD and lipid peroxidation 
Increased levels of oxidative stress correlate with disease severity in HIV-
associated cognitive impairment. Oxidative stress in the brain of HIV dementia 
patients is demonstrated by increased levels of sphingomyelin, ceramide and 4-
HNE, a lipid peroxidation product, produced through increased breakdown of lipid 
membranes. 
In HIV dementia an increase in sphingolipid levels is found secondary to impaired 











an increase in 4-hydoxynonenal (4-HNE), is associated with disease progression 
(Steiner, 2006). 
Sphingomyelin, ceramide and 4-HNE levels in the CSF show significant 
increases in patients with dementia (Sacktor, 2004; Pocernich, 2005). These 
increases of 4-HNE and ceramide in the CSF of active HAD and the increase of 
sphingomyelin, but not 4-HNE and ceramide, in inactive HAD may aid in the 
classification of HAD subjects according to disease severity (Sacktor, 2004; 
Bandaru, 2007). 
4.5 Protein Oxidation 
Oxidative damage includes damage to proteins and breakage of the 
deoxyribonucleic acid (DNA) strand. Damage result from direct insults to thiol 
groups, or indirectly through lipid peroxidation (Steiner, 2006). 
Reactive oxygen species cause oxidative damage to the amino acid side-chains 
of proteins with production of protein carbonyls. Protein oxidation is mediated 
through peroxynitrite (ONOD-), a powerful oxidant formed by a reaction between 
nitric oxide and superoxide, leading to formation of protein carbonyls. The 
structural damage to proteins results in breakdown of enzymes, impaired 
receptor-mediated cellular signaling, defective transport mechanisms, and 











4.5.1 HAD and protein oxidation 
Protein carbonyl levels are used markers of oxidative damage to proteins. HAD 
is associated with elevated levels of peroxynitrite, 4-HNE and protein carbonyls 
due to protein oxidation (Sacktor, 2004; Valcour, 2004; Pocernich, 2005). HIV 
proteins induce the formation of protein carbonyls independently and increased 
levels of protein carbonyls are associated with severe HIV-associated dementia 
(Turchan, 2003). 
HIV proteins mediate direct neurotoxicity through oxidative stress. Tat stimulates 
expression of iNOS, with production of nitric oxide and neurotoxic peroxynitrite 
(ONOO), after reacting with superoxide anions (02-). Tat protein increases 
intracellular calcium through mitochondrial dysfunction. Tat is also associated 
with elevated levels of protein carbonyls as a result of oxidative damage 
(Turchan, 2003). 
4.6 Oxidative stress induced by mitochondria 
Mitochondria produce oxidative stress through oxidative phosphorylation. 
Adenosine triphosphate (ATP) is synthesized by the respiratory chain during 
oxidative phosphorylation with utilization of oxygen (Emerit, 2004). Reactive 
oxygen species (ROS) are formed during the normal process of oxidative 
phosphorylation. 
The lipid peroxidation product, 4-HNE, impairs function of mitochondria. 
Mitochondrial dysfunction leads to overproduction of ROS during oxidative 











Oxidative stress related to impaired energy systems induced by mitochondrial 
failure lead to accumulation of extracellular glutamate. 
4.7 The role of APOE in oxidative stress 
The APOE E4 allele is associated with dysregulation of lipid metabolism. 
Sphingomyelin, ceramide and cholesterol levels are significantly increased in the 
presence of the APOE E4 allele (Steiner, 2006). The apolipoprotein E4 isoform 
is associated with accumulation of cholesterol during sphingomyelin breakdown 
due to impaired metabolism of cholesterol esters and triglycerides (Bandaru, 
2007). The increase in lipid oxidation is associated ith increased oxidative 
stress. 
Individuals who have an APOE E4 allele show increased markers of oxidative 
stress, an increase in mithochondrial dysfunction and decreased glutathione 
levels in HAD (Steiner, 2006). 
The APOE E4 allele is associated with an increased in lipid peroxidation and a 
decrease in anti-oxidant potential in the presence of HIV proteins, including tat 
(Pocernich, 2005). 
4.8 Anti-Oxidants and HAD 
Mitochondrial glutathione (GSH) is an endogenous electron donor which 
demonstrates anti-oxidant properties. GSH reduces ROS and nitrogen free 











Decreased levels of GSH are associated with increased oxidative stress. 
Decreased manganese superoxide dismutase levels are another indicator of 
increased oxidative stress (Pocernich, 2005). 
Glutathione forms an important part of the anti-oxidative stress response. 
Cystine is the rate limiting factor in glutathione production. After importation into 
the cell, cystine is reduced to cysteine. Cysteine is then transformed to gamma-
glutamyl-cysteine which reacts with glycine to form glutathione (GSH) (Alison, 
2007). 
Increased stimulation of protective pathways may idiosyncratically result in 
upregulation of glutathione production with increased cystine import and 
excessive export of glutamate. An excess in xtracellular levels of glutamate 
during oxidative stress impairs anti-oxidant mechanisms through suppression of 
cystine-release required for production of glutathione. 
Anti-oxidant defense systems provide further protection through manganese 
superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase 
and NADPH regenerating enzymes (Dheen, 2007). Manganese superoxide 
dismutase fulfills the role of an anti-oxidant and decomposes O2- into 02 and 
H20 2• HIV proteins directly impair anti-oxidant defense mechanisms through 
decreased levels of glutathione and manganese superoxide dismutase with an 
increase in oxidative stress (Emerit, 2004). Tat induces feedback inhibition of 
gluthathione synthetase with a further reduction of glutathione levels. The 
resultant glutathione deficiency impairs antioxidant mechanisms (Reynolds, 
2007). Decreased levels of glutathione in HIV infected patients were associated 











4.9 Hypotheses: Markers of Oxidative Stress 
In the light of this literature review we hypothesized that markers of oxidative 
stress in the peripheral blood will relate to markers of inflammation in the 
peripheral blood, as well as with markers in inflammation in the brain as 
measured by MRS in HIV-infected patients with cognitive impairment. We 
hypothesized that ORAC, as measure of total anti-oxidant capacity, will inversely 
relate to systemic markers of oxidative stress and markers of inflammation, both 
in the brain and peripheral blood. In addition we investigated the association of 
APOE E4 with oxidative stress in HAD. 
4.10 Method: Markers of Oxidative Stress and Anti-oxidant Capacity 
4.10.1 Thiobarbituric Acid Reactive Substances (TBARS) Method 
We mixed 501-11 of serum with 6.25 1-11 of butylated hydroxyl toluene (BHT) in 
ethanol and added 50 1-11 of 0.2molll orthophosphoric acid in 2ml Eppendorf micro 
test tubes. It was vortexed for 10 seconds. 
We added 6.25 1-11 thiobarbituric acid (TBA) reagent (0.11 moll!: TBA dissolved in 
50ml 0.1 molll sodium hydroxide (NaOH) and it was vortexed again. 
The mixture was then incubated at 90 degrees Celsius for 45 minutes in a water 
bath. 
The tubes were put on ice for two minutes to stop the reaction and then cooled to 
room temperature for a further 5 minutes. 
TBARS were extracted once with 500 1-11 butanol. 
50 1-11 saturated sodium chloride (NaCI) was added to facilitate phase separation 
and then centrifuged at 12000rpm for 1 minute. 











Absorption was read at 535nm and 572nm and the calculations made using the 
two wavelengths and previously prepared calibration curves (Jentzsch, 1996). 
4.10.2 Conjugated Dienes Method 
Lipid extraction was performed by the Folch method (Folch, 1957). 
Chloroform and methanol was mixed in a 2:1 ratio by volume. 
The serum sample was diluted with the chloroform methanol mixture to a 20 fold 
dilution of the original serum sample and mixed with water of 0.2 of the sample 
volume. 
The sample was then split into two phases by centrifugation at 2400rpm. The 
upper and lower phase was calculated in a 40% to 60% volume ratio. The upper 
phase was removed by pipette. 
The lower phase was then diluted in a 2: 1 ratio with the chloroform-methanol 
mixture (Vansankari, 1995). 
A double extraction was performed to ensure the purity of the lipids. 
The extract was then dried under nitrogen atmosphere. 
The dried lipid extract was diluted with chloroform and aliquotted into vials. 
The lipid sample was dried finally to ensure concentration of pure lipids (Folch, 
1957). 
The dried lipid was dissolved in cyclohexane to a lipid concentration of 100IJg/mi. 
The serum lipid per oxidation was read spectrophotometrically between 300 and 











4.10.3 lipid hydroperoxides (LOOH) Method 
The FOX assay was used to assess the amount of lipid peroxides in the 
samples. Reduction of peroxides by Fe2+ generates Fe3+ in acidified samples. 
The generated Fe3+ forms a complex with xylenol orange. The absorbance of 
the 1:1 XOI Fe3+ complex can be read at 560nm by spectrometry in which the 
concentration of lipid hydro peroxides is represented by the colour intensity. 
The Ferric-Xylenol Orange (FOX) reagent consisted of 90% of methanol, 10% 
250mM sulphuric acid (H2S04), 880mg of BHT, 98mg of ferrous ammonium 
sulfate hexahydrate (2501JM) and 76mg of xylenol orange (100 IJM). Two 
individual samples were prepared. The first with equal amounts of sample and 
10mM triphenylphosphine (TPP), a LOOH reducing agent which was combined 
in methanol by vortex and incubated for 30 minutes to allow complete reduction 
of -OOH. The second sample was prepared without the reducing agent, 
substituting the TPP with methanol. The FOX agent was added to both samples 
and the difference in absorbance read at 560nm exactly 10 minutes after the 
reagent was added. It was then read against a standard curve (DeLong, 2002). 
4.10.4 Oxygen Radical Absorbance Capacity (ORAC) Method 
The ORAC assay is an inhibition method. Inhibition of free radical action is 
measured after a free radical generator has been added to the sample. The 
fluorescence of R-phycoerythrin is measured as indicator of damage through free 
radical action. A decrease in fluorescence of R-phycoerythrin is an indicator of 
the anti-oxidant capacity of the sample. 2, 2' azobiz (2-amidinopropane) 
dihydrochloride is used as the free radical generator. The free radical action is 











We added 101-11 of 2,2' azobiz (2-amidinopropane) dihydrochloride to the reaction 
mixture. 
The reaction mixture consisted of 3001-11 R-phycoerythrin and 20 1-11 of Trolox (6-
hydroxy-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid) for acquisition of the 
standard curve. The sample mixture consisted of 3001-11 R-phycoerythrin and 
serum (1 :200 dilutions). The serum was prepared by precipitation of proteins 
through ethanol and the sample was diluted with a phosphate buffer (Wang, 
2004). 
TABLE 8: Descriptive data: Oxidative stress 
Variable Distribution HIV negative controls HIV -infected patients 
(N :::: normal) (n :::: 10) (n :::: 33) 
Median Median 
(Interquartile Range) (Interquartile Range) 
CD Non N 86.2 (74.2 - 98.7) 109.8 (70.8 -138.2) 
TSARS Non N 1.7(1.4-2.4) 1.2 (1.0 - 1.8) 
LOOH NonN 213.5 (180.2 - 268.7) 173.3 (143.0 - 215.7) 
Mean ± Standard Deviation Mean ± Standard Deviation 











TABLE 8: Descriptive data: Oxidative stress (Continued) 
Variable Distribution H IV-infected HIV-infected H IV-infected 
(N ::: normal) NPO NP 1 NP2 
Median Median Median 
(Interquartile Range) (Interquartile Range) (Interquartile Range) 
LOOH Non N 193.5 164.5 164.2 
(144.4 - 227.6) (132.8 - 188.4) (151.8 - 222.3) 
CD Non N 127.6 79.3 127.3 
(76.5 - 148.0) (64.8 - 126.5) (82.1 -154.0) 
TBARS Non N 1.2 (1.0 - 2.4) 1.2 (1.0 - 1.6) 1.5 (0.8 - 2.3) 
Mean ± Standard Mean ± Standard Mean ± Standard 
Deviation Deviation Deviation 










4.11 Results: Markers of Oxidative stress 
A significant inverse correlation between the marker of anti-oxidant capacity in 
the peripheral blood and a marker of brain inflammation, specifically glial 
proliferation, namely myoinositol, was found in HIV-infected participants with 
severe cognitive impairment. Oxygen Radical Absorbance Capacity (ORAC) 
correlated inversely with myo-inositol, measured at 30 milliseconds on MRS 
(Spearman's rank correlation coefficient = -0.587, P = 0.045, n = 12), results in 
figure 9. The correlation between decreased anti-oxidant capacity in the 
peripheral blood and increased glial proliferation may signify increased 
inflammation in the brain in a setting of impaired anti-oxidant defenses. Impaired 
anti-oxidative defenses relate to increased oxidative stress, which could mediate 
cognitive impairment in HIV-infected individuals (hypothesis 1.6.6). This finding 
supports our hypothesis (hypothesis 1.6.8) which relates impaired anti-oxidative 
defenses to an increase in inflammation in the brain of participants with HAD. 
Another systemic marker of oxidative stress correlated with inflammation in the 
brain (hypothesis 1.6.2). Lipid hydroperoxides, measured in the peripheral blood, 
showed a significant inverse correlation to N-acetyl aspartate, a marker of 
neuronal viability on MRS, in HIV-infected participants with severe cognitive 
impairment (Spearman's rank correlation coefficient = -0.697, P = 0.025, n = 10) 
results presented in figure 9. This supports the role of systemic oxidative stress 
in neurodegeneration associated with increased inflammation in the brain of 
patients with HAD (hypothesis 1.6.5). Increased systemic oxidative stress may 
relate to neuronal toxicity and loss. However, the numbers are small in this 
correlation and further studies with greater numbers are needed to validate the 











We found a significant correlation between conjugated dienes and TNF-a 
(Spearman's rank correlation coefficient::: 0.363, p-value 0.018, n ::: 42), results 
presented in figure 9. This relation between conjugated dienes and TNF-a 
relates to inflammation in the systemic circulation and cannot be extrapolated to 
the central nervous system. We screened for systemic causes of inflammation, 
but a systemic cause unrelated to inflammation in the brain might still explain the 
result. 
No further correlations were found between oxidative stress, anti-oxidant 
defenses and inflammatory markers systemically or in the brain measured with 
MRS. Neither levels of oxidative stress nor the anti-oxidant capacity differed 
significantly among the various HAD groups (hypotheses 1.6.4 and 1.6.7). 
We did not find correlations between the presence of the APOE E4 allele and 
either oxidative stress or anti-oxidant capacity in the peripheral blood in patients 
with HAD (hypothesis 1.6.12). 
In conclusion, we found significant relationships between systemic oxidative 
stress and inflammation in HAD. A marker of oxidative stress and a marker of 
inflammation in the brain, measured with MRS, correlated significantly in HIV-
infected patients with cognitive impairment. We also found a significant inverse 
relationship between the total anti-oxidant capacity in the blood and a marker of 
inflammation in the brain on MRS, in support of our hypothesis on the protective 
role of total anti-oxidant capacity in HAD. These findings support the role of 











TABLE 9: Results: Markers of Oxidative Stress 
myo-inositol N-acetyl aspartate TNF-a 
30 milliseconds 
Oxygen Radical Spearman's rank 
Absorbance correlation coefficient :::: 
Capacity (ORAC) -0.587 
p:::: 0.045 
n:::: 12 
lipid hydro- Spearman's rank 




conjugated Spearman's rank 














5. MAGNET\C RESONANCE SPECTROSCOPY 
5.1 The role of imaging in HAD 
Several radiological techniques has been used to evaluate changes in HAD 
including magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), 
diffusion weighted imaging (DWI), positron emission tomography (PET) and 
magnetic resonance spectroscopy (MRS). Various abnormalities on these 
radiological investigations are associated with HAD, of which the metabolites on 
MRS were used as surrogate markers of neuroinflammation in HIV-associated 
cognitive impairment in this study. Reduced levels of N-acetyl aspartate (NAA) 
and increased levels of myo-inositol represent neuronal loss and glial activation 
respectively and occur early in the disease. MRS markers relate to cognitive 
impairment, CD4 count, CSF and plasma viral load and severity of disease 
(Price, 2007) and MRS has been suggested for monitoring disease progression, 
with early initiation of treatment in patients at risk of cognitive impairment (Nath, 
2008). 
5.2 MRS Physics 
Magnetic Resonance Spectroscopy utilizes the nuclear magnetic resonance of 
individual molecules to obtain a magnetic spectrum. Proton spectroscopy CH-
MRS) relies on the spinning properties of protons to produce this magnetic 
resonance spectrum. When placed in a strong magnetic field, atoms with spin 
align themselves in relation to the magnetic field which is calculated in units of 
tesla. Magnetic resonance spectroscopy employs spinning of atoms and the 
magnetic properties related to it to achieve the spectrum of MRS. Molecules of 











differently in an applied magnetic field and these differences distinguish them on 
spectroscopy (Cady, 1990). 
5.3 Magnetic resonances 
The concentration of the metabolite is calculated by measuring the area under 
the metabolite peak of the resonances. Most of the relevant proton resonances 
are represented in a small bandwidth of 8 parts per million (ppm). One of the 
challenges faced in spectroscopy of the brain is the strong resonance due to 
tissue water. Water suppression pulses are used to diminish the resonance of 
the water molecules to permit interpretation of the various metabolite resonances 
of interest. Tissues with high magnetic susceptibility, including bone and 
sinuses, may produce artifact if the voxel is chosen too close to the structure. 
The artifact may broaden the spectrum to such an extent that the spectrum of the 
metabolites in question becomes indistinguishable (Cady, 1990). 
5.4 Chemical Shift Imaging (CSI) 
Spectroscopy is performed on either a single voxel, single voxel spectroscopy 
(SVS), or by involving multiple voxels, known as chemical shift imaging (CSI). In 
single voxel spectroscopy a single voxel, the size ranging from one to eight cubic 
centimeters, is used to evaluate a small area with high signal to noise ratio but 
partial volume effects may decrease specificity for focal metabolite abnormalities 
(Roc, 2007). Chemical shift imaging is more time consuming and produces a 
metabolite map of a larger area, which is subdivided in voxels of one cubic 











5.5 MRS of the brain 
The metabolites of note in spectroscopy of the brain include N-acetyl aspartate, 
myo-inositol, creatine, choline, lactate, lipids, and glutamine and glutamate. The 
resonances of different metabolites peak at different times in the spectrum of 
MRS. Depending on the metabolite in question, relevant parameters including 
repetition time and echo time needs to be selected. An echo time of 20-35 ms is 
applicable in metabolites whose relaxation time is relatively short, including myo-
inositol, glutamine and glutamate. Metabolites with long relaxation times, such 
as N-acetyl aspartate (NAA), creatine (Cr), choline (Cho) and lactate and lipids, 
require long echo times in the order of 135-270 ms. 
5.6 MRS in HIV 
HAD pathology studied with MRS shows a predilection for the subcortical gray 
matter (Chang, 1999). Structural abnormalities, with a decrease in volume, 
functional impairment of basal ganglia, and a decrease in metabolites, especially 
the lentiform nucleus (Meyerhoff, 1999; Roc, 2007), support involvement of the 
subcortical structures in HIV-associated cognitive impairment (Paul, 2007). 
Previously several studies reported improvement of metabolites on HAART 
including reversal of N-acetyl aspartate abnormalities (Roc, 2007). Correction of 
N-acetyl aspartate levels in patients receiving HAART implies a reversible 
pathological process underlying cognitive impairment and not necessarily 
irreversible damage due to apoptosis (Salvan, 1997). MRS detects abnormalities 
earlier than conventional magnetic resonance studies in the asymptomatic group 
of HIV infected patients. Early detection of a reversible cause in a patient with 











underlying pathology, rearborization of dendrites, and an improvement of 
cognitive impairment (Meyerhoff, 1993), 
In future, metabolites levels on MRS may be used in conjunction with other 
clinical measures to classify severity of cognitive impairment in HIV. MRS could 
play an important role in the evaluation and earty detection of changes in HIV 
infected patients (Salvan, 1997). 
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5.1 Metabolites on MRS in HAD 
5.1.1 N-Acetyl Aspartate 
Altered metabolites on MRS in HIV-associated cognitive impairment were first 
reported by Meyerhoff et al. (Meyerhoff, 1993). N-acetyl aspartate levels in HIV-
infected patients with cognitive impairment were significantly reduced compared 
to HIV-negative controls. The decrease in N-acetyl aspartate levels reflects 
neuronal damage and correlates with disease severity. 
N-acetyl aspartate peaks at 2,02ppm. It is the most prominent resonance in the 
spectrum and serves as a marker of integrity of neurons and axons. N-acetyl 
aspartate is located exclusively in neurons and decreased levels of N-acetyl 
aspartate on MRS point to neuronal damage (Salvan, 1997). The decreased 
level of N-acetyl aspartate is attributed to either permanent neuronal loss or 
possibly a reversible cause, including decreased dendritic arborization and 
axonal loss (Meyerhoff, 1993). 
N-actetyl aspartate levels in HAD are significantly decreased in groups with 
advanced disease and severe impairment of cognitive functioning (Meyerhoff, 
1999; Paul, 2007) compared to asymptomatic HIV-infected patients (Chang, 
1999; Gujar, 2005; Laubenberger, 1996). 
High levels of N-acetyl aspartate correlated with better scoring on 
neuropsychological tests. Decreased N-acetyl aspartate levels from the sub-
cortical areas, especially the lentiform nucleus and thalamus, correlated with 
impaired Z-scores on the Grooved Pegboard Test for fine motor and speed 











(Meyerhoff, 1999). Functional impairment correlated with testing of specific 
domains related to basal ganglia function (Paul, 2007). 
Confounding factors include age and CD4 count. N-acetyl aspartate levels are 
significantly affected by HIV independent of age (Chang, 2004), while CD4+ 
count did not correlate with N -acetyl aspartate levels in earlier studies (Salvan, 
1997). 
5.7.2 Myo-inositol 
Myo-inositol levels are increased in HIV-associated dementia. Myo-inositol is a 
marker of glial proliferation and levels increase during astrocyte proliferation. 
The myoinositol peak is seen at 3,56ppm in studies using a short echo time. 
Myo-inositol levels show significant changes in HIV infected individuals with 
cognitive impairment (Chang, 2004). Simultaneous raises in myo-inositol, 
choline and creatine on MRS are indicative of glial proliferation as shared 
underlying pathology in HIV dementia (Chang, 1999). Increased levels of myo-
inositol in the basal ganglia as measured by MRS are associated with cognitive 
impairment in HIV infected patients (Paul, 2007; Gujar, 2005). Elevated myo-
inositol levels in the basal ganglia of patients with cognitive impairment correlate 
with decreased scoring on neuropsycological testing (Paul, 2007). A study by 
Chang et a/. showed a significant increase in myo-inositol levels in a dose 
dependent manner according to the degree of cognitive impairment. 
The myo-inositol levels in HIV-infected subjects with cognitive impairment were 
higher compared to HIV-infected subjects who were asymptomatic or the control 











Myo-inositol levels are a more sensitive marker than choline levels in patients 
with moderate cognitive impairment and are elevated earlier than N-acetyl 
aspartate levels in HAND (Paul, 2007). Myo-inositol also serves as surrogate 
marker of an impaired blood brain barrier because of an increase in glial 
activation associated with indirect damage due to inflammation (Avison, 2004). 
Changes in myo-inositol levels correlate with a decrease in CD4+ count to below 
100 (Salvan, 1997). Myo-inositol levels are significantly affected by HIV 
irrespective of the changes in myo-inositol levels due to age (Chang, 2004). 
5.7.3 Choline 
Choline peaks at 3,2ppm. The peak represents all choline containing 
compounds including phosphocholine, glycerophosphocholine and 
phosphatidylcholine. They form part of cell membranes and increased choline 
levels are associated with increased membrane synthesis, an increased number 
of cells, increased membrane breakdown secondary to demyelination or tumour 
activity. 
Increased choline levels are present in most patients with HIV, including 
asymptomatic individuals (Gujar, 2005). Choline levels are higher in all groups of 
HIV infected patients with cognitive impairment compared to HIV-infected 
patients without cognitive impairment. High levels of choline are secondary to 
increased cell membrane turnover associated with apoptosis and glial 
proliferation (Meyerhoff, 1996; Meyerhoff, 1999). Increases in choline levels 
correlate with the degree of severity of cognitive impairment in HIV infected 











ganglia was associated with cognitive impairment in HIV-infected patients (Paul, 
2007; Chang, 2004; Meyerhoff, 1999). 
CD4+ count related to choline levels in a concentration-dependent manner 
(Salvan, 1997). Choline levels in the basal ganglia are significantly affected by 
HIV independent of age (Chang, 2004). Reversal of choline abnormalities on 
HAART supports a reversible pathological process underlying cognitive 
impairment, thus advocating early detection of cognitive impairment in order to 
initiate HAART (Roc, 2007). 
5.1.4 Creatine 
I n this study creatine was used as reference value to calculate the N-acetyl 
aspartate and myo-inositol ratios. The creatine peak represents phosphocreatine 
and occurs at 3,Oppm. It is a marker of brain metabolism and due to the stability 
of creatine it is used as a reference value to calculate metabolite levels. Creatine 
levels on MRS do not differ among HIV-infected subjects, HIV-negative controls 
(Meyerhoff, 1993) or HIV-infected subjects grouped according to degree of 
cognitive impairment (Meyerhoff, 1999; Chang, 1999). The stability of total 
creatine renders it the ideal standard reference (Laubenberger, 1996; Chang, 
1999; Chang, 2004). 
5.1.5 Lactate and Lipid 
Other metabolites which have significance in MRS studies of HIV related 











Lactate forms a doublet peak at 1,33ppm. At low echo times (TE) of 20 to 35ms 
and very high· echo times of 270 to 288ms lactate forms a peak above the 
baseline. At intermediate echo times (TE) of 135-144ms the lactate peak inverts 
to form a peak below the baseline which distinguish lactate from lipids and other 
macromolecules in the same location. Lactate is at or below detection levels in 
the normal brain. The lactate peak represents hypoxia, ischaemia, tumours or 
mitochondrial disorders and increases during anaerobic glycolysis and with 
impaired oxidative phosphorylation. 
Elevated lactate levels are a marker of anaerobic oxidation and inflammation in 
subjects with severe cognitive impairment. In the final irreversible stages of 
dementia leakage of lactate hydrogenase during apoptosis may contribute to the 
elevation of lactate (Roc, 2007). Lipid and lactate show promise as sensitive 
markers of cognitive impairment in patients on treatment, because they remain 
unaltered regardless of HAART (Roc, 2007). 
The lipid resonance is found at 0,9ppm to 1.5ppm. Elevated lipid levels are 
secondary to an increase in membrane turnover. Oxidative stress, with 
associated lipid peroxidation, and necrosis of brain tissue, seen in tumours, 
cause an elevation of the lipid peak. Subcutaneous fat is a possible source of 
contamination of the resonance. 
Increased lipid levels were found in HIV infected subjects with no or mild 
cognitive impairment and are attributed to increased lipid peroxidation associated 
with membrane turnover in oxidative stress. Elevated lipid and lactate levels in 
all subgroups of patients suggest the presence of oxidative stress early in the 
disease process which persists as the disease progresses. Continued lipid 
elevation after initiation of HAART may point to an irreversible component of lipid 











oxidative stress and inflammation in the presence of HAART, implies impaired 
penetrance of HAART with continued viral replication and progression of 
neurological disease despite therapy (Roc. 2007). 
5.7.6 Glutamate and glutamine 
Glutamate and glutamine produce multiple resonances between 2,2ppm and 
2,4ppm when using short echo times. Glutamate increases in conditions causing 
hyperammonemia, for example in hepatic encephalopathy, but no significant 
changes in glutamate or glutamine are found in HIV-associated cognitive 











FIGURE 7: MRS in HAD (Roc AC etal. Arch Neurol. 2007; 64(9); 1249-1257) 
The study by Roc e/ ai. compared MRS of the lentiform nuclei in participants with various 
degrees of cognitive impairment. 
Spectrum A: MRS performed on a HIV-negative control. The NAA peak represents 
viable neurons. Note the absence of a lipid and lactate peak. 
Spectrum B: A HIV-infected participant with mild cognitive impairment There is a lipid 
and lactate (lip+Lac) peak visible, indicating the presence of anaerobic respiration. 
Spectrum C A HIV-infected participant with moderate cognitive impairment. The lipid 
and lactate and choline (Cho) peaks represent cel l damage assOCiated with HAD 
Spectrum D: MRS in a HIV-infected participant with severe cognitive impairment The 










5.B Hypotheses: Magnetic Resonance Spectroscopy 
In the light of the existing data on MRS in HAD presented, we employed MRS to 
measure metabolites in tile brain as markers of inflammation in the brain in HAD. 
Our hypothesis was that markers of inflammation on MRS in the brain will relate 
to systemic markers of inflammation and oxidative stress in HIV-infected patients 
with cognitive impairment We also looked for a relationship between brain 
infiammation on MRS and the APOE E4 allele. 
5.9 Method: Magnetic Resonance Spectroscopy 
Magnetic Resonance Spectroscopy was performed on a Siemens 3 Tesla 
Magnetom Allegra Scanner. Two CSI MRS sequences were performed; one with 
an echo lime (TE) of 30 milliseconds and another with an echo time of 135 
milliseconds. The short echo time measured metabolites with a short relaxation 
time, including myo·inositol. and the long echo lime measured metabolites with 
long relaxation times such as N·acetyl aspartate. The repetition time was 2000 
milliseconds. Tile voxel size in the grid was 1.3cm X 1.3cm X 2.00cm with a 
matrix size of 16 voxels X 16 voxels. MRS slices included deep gray matter of 
the lentiform nucleus. Voxels were chosen to avoid close proximity to the 
ventricles. limi ting the pos ibility of interference by water resonance. Water 
suppression was achieved by pre-scanning the patients to obtain tile water 
resonance value. Acquisition lime amounted to 8 minutes. 
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FIGURE 8: MRS Spectrum from this st udy: HIV·infected patient at echo time (TEJ 
30 millisoconds 
The N-acetyl aspartate (2,02ppm), myo·inositol (3,56ppm), choline (3,2ppm), 
creallne (3,Oppm ), lipid (O, 9ppm) and lactate (1 ,33ppm) peak.s are demonstrated. 
Slight drift of the baseline demonstrate some of the technical difficulties 
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FIGURE 9: MRS Spectrum from this study: HIV·infected patient at echo time (TEl 
135 milliseconds 
Note the prominent N·ac tyl aspartate peak (2,02ppm) evtdent at 135 
milliseconds, The creatine peak can be seen at 30ppm. Choline (3,2ppm) and 
m~·inositol (3,56ppm) peaks are present. The laller may relate 10 increased 
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FIGURE 10: MRS Spectrum from this study: HIV-infected patient at echo lime (TEl 
30 milliseconds 
The N-acetyl aspartate p ak (2 ,02ppm) IS present l (lctale ( 1,33ppm" choline 










TABLE 10: Descriptive data: Magnetic Resonance Spectroscopy 
Variable Distribution HIV negative controls HIV -infected patients 
(N:: normal) (n :: 10) (n :: 33) 
Median Median 
(Interquartile Range) (Interquartile Range) 
NAA30 Non N 1.1 (0.5 - 1.5) 1.2 (0.4 - 2.1) 
MI30 Non N 0.7 (0.4 - 0.9) 0.7 (0.6 - 0.9) 
Lactate 30 Non N 0.6 (0.5 - 1.4) 0.5 (0.4 - 1.3) 
NAA 135 Non N 1.4 (1.5 - 1.6) 1.3 (1.5 -1.7) 
MI135 Non N 0.9 (0.8 - 1.0) 0.82 (0.75 - 1.0) 
lactate 135 Non N 0.6 (0.4 - 10.5) N/A 
NAAN/NAAG 135 Non N 1.4(1.4-1.5) 1.5(1.4-1.7) 
Variable Distribution HIV-infected HIV-infected HIV-infected 
(N == normal) NPO NP 1 NP2 
Median Median Median 
(Interquartile (I nterquartile (Interquartile Range) 
Range) Range) 
NAA30 Non N 1.2 (0.9 - 1.5) 0.9 (0.1 -1.4) 1.0 (0.3 - 1.5) 
MI30 Non N 1.5 (0.3 - 2.7) 0.9 (0.5 - 1.3) 0.8 (0.4 - 1.2) 
Lactate 30 Non N 0.4 (0.4 - 1.1) 1.1 (0.6 -1.7) 0.45 (0.4 - 0.53) 
NAA 135 Non N 1.5 (1.4-1.6) 1.5(1.3-1.7) 1.4(1.2-1.5) 
MI135 Non N N/A N/A N/A 












5.10 Results: Magnetic Resonance Spectroscopy 
We found significant correlations between markers of systemic inflammation and 
markers of inflammation in the brain on MRS. Results have been discussed in 
the chapter on inflammation (see section 3.8). We also found significant 
associations between markers of inflammation in the brain on MRS and systemic 
oxidative stress and anti-oxidant capacity (see section 4.11). Results on 
inflammation in the brain on MRS which has not been presented in the chapters 
on systemic markers of inflammation and oxidative stress will now be discussed. 
Increased levels of lactate, measured at an echo time of 135 milliseconds, 
correlated with an increased white cell count in the peripheral blood (Spearman's 
rank correlation coefficient == 0.829, p-value 0.042, n == 6), table 11. The increase 
in white cell count, a marker of systemic inflammation, relates systemic infection 
to brain inflammation, as measured by lactate, marker of anaerobic respiration. 
The correlation coefficient is quite strong but the result should be interpreted in 
the light of the small sample size and the p-value which is not strongly significant. 
Inflammation in the brain measured with MRS did not differ significantly among 
the various HAD groups (hypothesis 1.6.9). The APOE E4 allele did not show 
significant correlations with inflammation in the brain as measured on MRS and 
HAD (hypothesis 1.6.13). 
These findings prove our hypotheses that markers of inflammation in the brain on 
MRS correlate with systemic markers of inflammation and oxidative stress, 











impairment. Our findings support the presence of a relationship between 
systemic inflammation and inflammation in the brain in HAD. 
TABLE 11: Results: Magnetic Resonance Spectroscopy 
White cell count 














6. The Apoliprotein E Genotype 
The apoliprotein E4 (APOE E4) allelic variant of the apolipoprotein E (APOE) 
gene is associated with an increased risk of cognitive impairment in 
neurodegenerative diseases and in HIV-infected patients (Deary. 2002). The 
APOE E4 allele has several associations with HIV. The presence of the APOE 
E4 allele is associated with a greater risk for cognitive impairment in patients with 
reduced CD4+ counts and increased viral loads (Corder, 2007; Burt, 2008). 
Amyloid beta deposits are increased in HIV dementia and this may, in the 
presence of the APOE E4 allele, predispose patients to cognitive impairment. 
Allelic frequencies of APOE E4 are especially high in African populations, 
possibly placing them at risk for increased cognitive impairment (Sand holzer, 
1995; Gerdes, 2003). The presence of the APOE E4 allele has been associated 
with acceleration of disease and faster progression to death (Burt, 2008). The 
association between APOE E4 and HAD may be age-dependent, with an 
increased risk of cognitive decline in older HIV infected patients (Pomara, 2008; 
Valcour, 2004). 
The apoliprotein E4 (APOE E4) allele has been associated with an increased risk 
for neurodegenerative diseases including, Alzheimer's disease, earlier onset of 
Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis (Deary, 
2002). The APOE E4 allele is associated with accelerated cognitive decline in 
the elderly and in HIV infected patients. Increased glial activity, over-expression 
of cytokines and augmentation of direct effects of viral proteins, lead to 
accelerated cognitive decline in the presence of the APOE E4 allele. 
Neurodegeneration is accelerated in the presence of the APOE E4 allele due to 
impaired neuronal repair mechanisms in the presence of increased inflammatory 
mediators secondary to chronic activation of microglia by HIV. Impaired neuronal 











genotype is associated with an increased risk of cognitive impairment in HIV-
infected patients. HIV-infected subjects with an APOE E4 allele show an 
increased prevalence of mild suspected dementia (30% versus 15%). 
Neuropathy is also increased in frequency and severity (70% versus 39%) in HIV 
infected patients with an APOE E4 allele (Corder, 1998). 
6.1 APOE Genetics 
The apolipoprotein E (APOE) gene is situated on chromosome 19, location 
19q13.2, and is formed by 3597 base pairs. The APOE gene shows 
polymorphism and has common three alleles APOE E2. APOE E3 and APOE 
E4. The polymorphisms are situated on exon 4 in pOSitions 3937 and 4075. 
The APOE gene codes for the apolipoprotein E (ApoE) protein. ApoE is a 34 
000 molecular weight glycoprotein of 299 amino acids which consists of two 
structural domains separated by a hinge region. The N-terminal domain forms a 
four helix anti-parallel bundle which contains the receptor binding region. The N-
terminal domain is formed by amino acids 1-191 and the receptor binding region 
by amino acids 134-150 and Arg-172. The C-terminal domain contains the major 
lipid binding region formed by amino acids 244-272 (Mahley, 2009). The amino 
acid sequences differ between the three isoforms due to isoform-specific 
inclusion of cystein and arginine in positions 112 and 158. ApoE2 has two 
cystein amino acids in position 112 and 158 while ApoE3 has a cystein and an 
arginine and APOE4 has an arginine amino acid in both positions. The 
differences in the primary structure of the isoforms lead to differences in 
secondary and tertiary structures and function (Gerdes. 2003). Arginine-112 
alters the structure of apolipoprotein E4, resulting in increased binding to large 











preferred binding of the E2 and E3 isoforms to small phospholipid-rich receptors 
(Mahley, 2009). 
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FIGURE 11: The APOE Gene 
Cytogenetic Location 19q13.2 
Molecular Location on chromosome 19: base pairs 50,100,878 to SO,1 04,489 
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The Apolipoproleln E4 Isofonn demonstrates the ability of AJY-11 2 10 bind to Arg-61. 











APOE E4 is the proposed ancestral allele of the APOE gene. The position of the 
polymorphism on the gene favors the formation of E3 from E4 rather than the 
reverse and social studies relate the increased prevalence of APOE E4 in the 
African population to the later origin of APOE E3 in the era of the modern man. 
A hypothesis of selective pressure driven by infectious diseases is proposed to 
explain the difference in allelic frequencies of APOE. 
Dominance of the APOE E3 allele in Caucasian populations might have evolved 
through selection against the E4 allele by viral infection on migration to Europe. 
Preferential death of APOE E4 allele carriers in a cataclysmic infective insult, for 
example the great plague, could have caused dominance of the E3 allele 
(Mahley, 2009). The difference in distribution of APOE polymorphisms between 
population groups has also been related to diet. The APOE E3 allele is more 
prevalent in populations of agricultural background and a stable food supply, 
where APOE E4 is present in populations where food has been scarce and only 
intermittently available (Corbo, 1999). The hypothesis of preservation of the 
APOE E4 allele from extinction in foraging populations is associated with 
advantages associated with increased absorption of fat from the intestine 
providing effective survival during famine. The tendency of an increased 
frequency of APOE E4 allele in the north of Europe supports this hypothesis with 
persistence of the APOE E4 allele in the hunter/gatherer population of the north 
despite later inward migration of agricultural farmers. 
The APOE E2 allele is least frequent and the E3 allele most frequent. The allelic 
frequencies in the majority of studies from North America and Europe are quoted 











quoted are 0.5% for E2/E2. 11 % for E2/E3, 2% for E2/E4, 59% for E3/E3, 25% 
for E3/E4 and 3% for E4/E4 (Corder E.H., 1998; Farrer, 1997). 
APOE E4 frequency is relatively high in African population. In the Asian 
populations the E4 allele is less frequent and the homozygous E4 state is 
associated with a significant increase in risk of AD in the Japanese population 
(Farrer, 1997). The higher frequencies of APOE E4 in the foraging population 
include the Khoi-San (0.370). Pygmies (0.407). Australians (0.260). Aborigines of 
Malaysia (0.240), Papuans (0.368), Native Americans (0.280) and Lapps (0.310). 
Studies based on Nigerian populations also showed higher APOE E4 allelic 
frequencies of 0.217 and 0.310 (Sahota, 1997; Eichner, 2002; Gureje, 2006). 
The homozygous APOE E4 genotype is 3-5 fold more common in the Khoi-San 
population compared to Caucasians (10% versus 2-3%) and a study in the 
Shona of Zimbabwe revealed equally high allelic frequency of E4 (22.3%) and a 
homozygous E4 genotype frequency of 5.9% (Tanayanyiwa). Populations with a 
foraging decent, like the Khoi-San, may have a genetic predisposition to these 
disorders when exposed to the Western lifestyle (Sandholzer, 1995; Gerdes, 
2003). Atherosclerosis and Alzheimer's disease have been associated with 
APOE E4 allele, Western diet and longevity. 
6.3 lipid Metabolism and APOE 
ApoE is produced within the brain and does not need to cross the brain barrier 
(Guo, 2004). In the central nervous system ApoE is secreted mainly by 
astrocytes, but neurons and other activated microglial cells may secrete ApoE in 











oxidative stress (Mahley, 2009). ApoE is involved in neuroprotection through 
redistribution of lipids involved in neuronal repair (Mahley, 2009). 
Apolipoprotein E regulates cholesterol metabolism utilizing low density lipoprotein 
(LDL) receptors for transport and metabolizing lipoproteins containing cholesterol 
and triglycerides. Apolipoprotein E4 binds to triglyceride rich, very low density 
lipoproteins receptors in contrast to preferred binding of the E2 and E3 alleles to 
small phospholipid-rich receptors (Mahley, 2009). Binding to very low density 
lipoproteins receptors predisposes apolipoprotein E4 to increased clearance. 
The accelerated clearance of apolipoprotein E4 leads to decreased levels of 
apolipoprotein E4 in the serum and CSF, and an increased rate of 
neurodegeneration secondary to impaired protective mechanisms. Decreased 
levels of apolipoprotein E4 secondary to preferential degradation could lead to 
impaired neuronal regeneration precipitated by a decrease in cholesterol delivery 
to neurons. The decreased availability of cholesterol is associated with impaired 
protective mechanisms, including a decrease in synaptogenesis, dentrite 
branching and axonal repair. Neurite branching is less extensive in the presence 
of the APOE E4 allele compared to APOE E3 (Turchan-Cholewo, 2006) and 
inadequate regeneration of neurons following injury may accelerate 
neurodegeration in the presence of the APOE E4 allele compared to the other 
polymorphisms. These impaired protective mechanisms are associated with 
increased membrane damage and apoptosis compared to the APOE E3 allele 
(Riddel, 2008; Mahley, 2009). 
The E4 isoform of apolipoprotein differs structurally from the other 
polymorphisms and is inherently more unstable due to its molten globule state. 
The structural differences increase the proteolytic tendency of ApoE4 and 











proteolytic cleavage to a much greater extent than ApoE3 (Riddel, 2008). The 
increased breakdown of ApoE is associated with accumulation of cytotoxic 
proteolytic fragments in the cytosol which cause neurotoxicity and 
neurodegradation (Riddel, 2008; Mahley, 2009). 
6.4 APOE and inflammation 
ApoE is involved in pro-inflammatory and anti-inflammatory responses in the 
central nervous system. ApoE mediates an anti-inflammatory response by 
decreasing glial cell activation, with a concomitant reduction in the production of 
ApoE. These anti-inflammatory changes are genotype-specific and the APOE 
E4 allele displays impaired anti-inflammatory modalities, with persistence of the 
amyloid beta-associated inflammatory stimulus. This results in decreased 
suppression of amyloid beta secretion with an increase in amyloid beta load 
(Guo, 2004). 
ApoE4 demonstrates independent pro-inflammatory properties, seen as an 
increase in production of IL-1 J3. ApoE4 is associated with a significantly greater 
increase in IL-1 J3 compared to Apolipoprotein E3 (Guo, 2004). A selective 
increase in IL-1 J3 levels is present despite inhibition of the amyloid beta-related 
inflammatory response by ApoE. Apolipoprotein E4 stimulated interleukin-1 beta 
independent of amyloid beta in an isoform dependent manner. Some studies 
reported an increased inflammatory response with increased cytokine production 
of TNF-a in individuals with an APOE E4 allele compared to subjects without the 












6.5 Impaired protection against oxidative stress associated with APOE 
ApoE is involved in anti-oxidant homeostasis and the APOE E4 allele may be 
less protective against oxidative insults than the E3 allele. Increased microglial 
responsiveness may be responsible for early neurodegeneration in subjects with 
an APOE E4 allele secondary to excessive oxidation and nitration of neuronal 
cells. 
Mitochondria are involved in plasticity, synaptogenesis and neuronal dendrite 
growth and ApoE E4 induced mitochondrial toxicity manifests through impaired 
dendrite formation and neurotoxicity (Mahley, 2009). Decreased suppression of 
amyloid beta by APOE E4 leads to activation of macrophages and astrocytes 
with increased production of nitric oxide synthetase (Guo, 2004). Reactive 
nitrous oxygen species (RNOS) are involved in neurodegenerative processes in 
the central system and the APOE E4 allele is associated with augmentation of 
the inducible nitric oxide synthetase (iNOS) pathway in macro phages resulting in 
higher levels of NO. The increased cumulative redox imbalance is cytotoxic, 
causes neurotoxicity and predisposes an individual with an APOE E4 allele to 
accelerated neurodegeneration (Colton, 2004). The allele specific anti-oxidant 
capacity predisposes a subject who has an E4 allele to microglial-associated 
inflammatory damage due to impaired anti-oxidant defenses (Valcour, 2004). 
6.6 APOE and Alzheimer's Disease 
The APOE E4 allele is associated with an increased risk for development of 
Alzheimer's disease (AD). The amyloid related mechanism involved in AD 
associated cognitive decline may share a pathological mechanism with cognitive 











dependent way. An eightfold increase in risk is associated with the homozygous 
state of APOE E4 compared to heterozygous individuals (Corder, E.H., 1998). 
The homozygous state was associated with an increased risk in all races, but 
African-Americans had a weaker association than other races (OR 5.7 compared 
to an OR of 12.5 and 33.1 in Caucasians and Japanese respectively) (Farrer, 
1997). The E2 allele is associated with a protective effect, but due to the relative 
infrequency of this allele difficulty in achieving numbers impairs acquisition of 
data (Corder, E.H., 1998). 
6.7 APOE and amyloid deposition in Alzheimer's Disease 
The pathophysiology of Alzheimer's disease relates t  amyloid beta levels with 
associated glial activation. The decreased levels of apolipoprotein E4 lead to 
decreased clearance of amyloid beta with an increased burden of amyloid beta. 
The excess amyloid beta results in amyloid beta-associated glial activation with 
increased neuroinflammation (Riddel, 2008). Glial activation is modified in the 
presence of the APOE E4 allele and may influence disease progression in 
several ways. AD has been associated with increased inflammation due to 
excess glial activation in the presence of beta-amyloid plaques. Increased 
activation of glial cells n the presence of amyloid beta may lead to neurotoxicity 
due to excess secretion of cytokines and inflammatory mediators. Activated glial 
cells secrete ApoE to attenuate the inflammatory response associated with 
amyloid deposition. ApoE associates with amyloid beta, forms complexes and 
facilitate clearance of beta-amyloid via lipoprotein receptors. 
Diffuse plaques found in HIV infected patients is a precursor of plaques 
associated with AD and cognitive decline. CSF amyloid beta 1-42 levels are 











6.8 APOE and Inflammation in Alzheimer's Disease 
AD is associated with increased levels of pro-inflammatory cytokines, including 
IL-1 and IL-6. In the absence of the APOE gene there is an increase in the levels 
of IL-1 J3, IL-6, TNF-a and other inflammatory cytokines, demonstrating the anti-
inflammatory properties of apolipoproteins (LaDu, 2001). The increase in 
neuroinflammation in subjects with AD who have an APOE E4 allele is secondary 
to a relative decrease in APOE E4 levels compared to other APOE isoforms 
(Guo, 2004). Neurological symptoms in HIV infection share common underlying 
pathological mechanisms with Alzheimer's disease. An increased level of TGF-
1 J3 was present in subjects with AD compared to controls (Finch, 2007). 
6.9 APOE and Infection in Alzheimer's Disease 
Infectious agents have been implicated in AD in association with the APOE 
genotype. The APOE E4 allele may render the brain vulnerable to infection-
related damage due to ineffective repair with resultant cognitive impairment. The 
APOE E4 allele is more prevalent in AD patients infected with Herpes simplex 
virus type-1 (HSV1) (ltzhaki, 2010; Honjo, 2010; Honjo, 2009; Dobson, 2003). 
HSV1 may playa role in Alzheimer's related cognitive decline, with HSV1 DNA 
present in beta-amyloid plaques. 
6.10 Predisposing factors to HAD in the presence of the APOE E4 allele 
Other risk factors for cognitive impairment in the presence of the APOE genotype 
have been identified, including age, gender and stress levels. A significant 
increased risk of cognitive impairment is present in subjects with an APOE E4 











Studies found the risk of cognitive decline to be increased between the ages of 
40 and 60 years with a subsequent decrease. 
The association between APOE E4 allele and HIV-associated dementia (HAD) 
might be age-dependent (Pomara, 2008). Age has a modulatory effect on HIV-
associated cognitive impairment in the presence of the APOE E4 allele (Valcour, 
2004; Burt, 2008). The Hawaii Aging with HIV Cohort found a significantly 
increased incidence (40%) of HAD in an older age group above 50 years in the 
presence of one or more APOE E4 alleles compared to 17% in subjects without 
an APOE E4 allele (Valcour, 2004). 
Female sex is significantly associated with an increased risk for AD and may be 
a dominant risk factor (Farrer, 1997). Individuals with an E4 allele who are 
exposed to stress have an increased susceptibility to cognitive decline compared 
to individuals without an E4 allele (Peavy, 2007). 
Impaired immune function secondary to decreased ApoE4 levels may predispose 
an individual to impaired neuronal repair and increased neurodegeneration. 
Neuronal repair is dependent on normal immune function (Colton, 2004). 
Antigen-presenting cells secrete apolipoproteins to bind serum-borne lipid 
antigens. Bound antigens are delivered to the endosomal compartments of 
antigen presenting cells by apolipoproteins. Apolipoproteins mediate T-cell 











6.11 APOE in HIV 
Apolipoprotein E is involved in cholesterol metabolism. In the brain astrocytes 
and microglia are primarily involved in the secretion of cholesterol. Cholesterol 
forms part of the HIV envelope and variance in lipid metabolism between APOE 
isoforms may alter cholesterol metabolism and influence the HIV disease 
progression (Burt, 2008; Mahley, 2009). 
The homozygous state of the APOE E4 polymorphism showed a significant 
acceleration of HIV disease progression due to an increased rate of HIV 
infection. Apolipoproteins act as viral fusion inhibitors due to their homology to 
the fusion domains of viral fusion proteins and interact with HIV 41 through 
amphipatic helices, with inhibition of viral fusion. APOE E4 inhibits fusion less 
efficiently than the E3 allele, predisposing cells to a higher frequency of HIV-
target cell fusion and an increased rate of viral entry. An accelerated mortality 
associated with the homozygous state of APOE E4 allele is attributed to 
increased entry of HIV in the presence of the APOE 4 allele (Burt, 2008). The 
APOE E4 allele is possibly associated with a shortened survival in subjects with 
the APOE E4 allele (Valcour, 2008). The altered fusion properties of APOE E4 
additionally predispose subjects to viral infection including HSV and susceptibility 
to opportunistic infections (Mahley, 2009) which may relate to the increased 
susceptibility to viral infections seen in individuals with AD. The presence of the 












6.11.1 Oxidative stress and APOE in HAD 
Products of lipid metabolism are increased in patients with HAD secondary to 
oxidative stress and the APOE E4 allele is associated with increased levels of 4-
HNE in neuronal cells, indicating a relative increase in oxidative stress and 
neuronal loss (Turchan-Cholewo, 2006). Polyunsaturated fatty acids are broken 
down by free radicals leading to the production of aldehydes including 4-HNE. 4-
HNE may impair mitochondrial function leading to further oxidative stress 
(Turchan-Cholewo, 2006). 
6.11.2 APOE and HIV proteins 
Neurotoxicity associated with HIV proteins is amplified by the presence of the 
APOE E4 allele. Amplified neurodegeneration in the presence of the APOE E4 
allele may be related to increased neurotoxicity caused by higher levels of 
oxidative stress mediated by the HIV tat protein (Turchan-Cholewo, 2006). The 
presence of HIV proteins, gp120 and tat, is associated with increased levels of 
oxidative stress and neurotoxicity in subjects with an APOE E4 allele compared 
to subjects without an APOE E4 allele. It presents in a dose dependent manner 
with maximal toxicity in homozygous individuals. Tat protein increases oxidative 
stress and impairs mitochondrial function. 
6.11.3 APOE and CD4 count 
A low CD4+ count is an independent risk factor for dementia. CD4+ count 
correlates with HAD. A CD4+ count of less than 100 is associated with disease 











the nadir of the CD4+ count being the most valuable predictor (Brew, 2008; Nath, 
2008). 
The rate of cognitive impairment is dependent on the APOE genotype and the 
CD4+ count in HAD. Patients with the APOE E4 allele has a faster rate of 
decline with decreased CD4+ counts compared to groups without the APOE E4 
allele. The APOE E2 allele shows the slowest decline in CD4+ count in a dose 
dependent manner, with stable CD 4 counts and delayed cognitive decline in the 
homozygous APOE E2 genotype (Corder, 2007). 
6.11.4 APOE and Viral load 
A high viral load is associated with the APOE E4 allele in a dose dependent 
manner (Valcour, 2004). 
6.12 The potential benefit of APOE genotyping 
APOE genotyping may provide benefit in management of HIV infected individuals 
in future. Differences in host-viral interaction with accelerated progression of 
disease depending on the APOE genotype, suggest early genotyping and 
initiation of HAART to alter disease progression. Development of APOE E4 
targeted therapeutic agents should be considered in HIV related pathology due to 











6.13 Hypotheses: APOE E4 Allele 
Literature reviewed in the previous sections suggests a role of the APOE E4 
allele in the pathogenesis of HIV-associated cognitive impairment. We 
hypothesized that the APOE E4 allele relates to markers of systemic 
inflammation, systemic markers of oxidative stress and inflammation in the brain 
measured by MRS. 
6.14 Method: APOE genotyping 
prepGEMTM was used to prepare single DNA strands for DNA extraction. 
prepGEMTM lyse cells and strips DNA from nucleoproteins. The DNA was then 
used to determine the APOE genotype. 
The method was performed in a DNA free environment to prevent contamination. 
Blood samples were collected from patients at their physical examination 
following informed consent. Blood samples were frozen within 1 hour of 
collection. Samples of whole blood, stored in citrated tubes in a minus 70 
degrees Celsius freezer, were used for DNA extraction. 
We used the method describe by Hixson (Hixson, 1990). ApoE restriction 
enzyme isoform genotyping (restriction genotyping) were used to amplify 
apolipoprotein E gene sequences containing the amino acid position 112 and 
158. The amplification products were digested and subjected to electrophoresis. 
Subsequent typing of homozygotic and heterozygotic combinations of the 
individual apolipoprotein E alleles was performed. This enabled us to calculate 












6.15 Results: APOE Genotype 
6.15.1 Allelic frequencies of HIV-infected Participants 
The allelic frequencies and genotype frequencies are tabulated in table 12. 
TABLE 12: APOE frequencies (n:::: 35) 











6.15.2 Allelic frequencies of the Newborn Controls 
300 stored cord blood samples, collected from black newborn babies, were 
genotyped to establish the population frequency of APOE. The allelic frequencies 











TABLE 13: APOE Population frequencies (n = 300) 











6.15.3 APOE Allelic frequencies compared 
The genotyping of our study group and the 300 standard samples is in keeping 
with reported data with the dominant allelic frequency of E3 with 58.1 % and 50% 
respectively and the dominant genotype of E3/E4 (39.5% and 30% respectively). 
The frequency of the E4 allele is much higher than the Caucasian, and even non-
Caucasian standards, in literature with an E4 allelic frequency of 33.7% in the 
study group and 30% in the standard samples, compared to 16% reported in 
literature. The results on the homozygous E4 genotype (11.6% in the study 
population and 9.6% in the standard samples) are in keeping with the findings on 
the Khoi-San (10%) (Sand holzer, 1995) and the Shona (14,8 %) (Tanayanyiwa), 
but much higher than the reported prevalence in the Western population (3%) 











TABLE 14: The APOE E4 allelic frequency grouped according to cognitive 
impairment 
Cognitive Function E4 Allelic Frequency Percentage 
NP::::: 0 (n::::: 9) 9 26.5 
NP::::: 1 (n::::: 13) 13 38.2 
NP::::: 2 (n::::: 12) 12 35.3 
Total 34 100 
The allelic frequency across the different groups of cognitive impairment was not 
significant (hypothesis 1.6.10). HIV-infected participants without cognitive 
impairment, HIV-infected participants with mild cognitive impairment and HIV-
infected participants with dementia showed similar APOE E4 allelic frequencies. 
The APOE genotype of HIV-infected participants without cognitive impairment 
compared to HIV-infected participants with severe cognitive impairment was also 
not significant (Chi-squared::: 0.43, p ::: 0.56) 
Further, the APOE genotype did not correlate with markers of systemic 
inflammation, markers of oxidative stress or markers of inflammation in the brain 
on MRS of patients with HAD (hypotheses 1.6.11,1.6.12 and 1.6.13). 
6.15.4 Results: The APOE E2 allele 
We did not find a significant difference between the frequency of the APOE E4 
allele in the HIV-infected population and the newborn population. However, the 
allelic frequency of the APOE E2 allele in the HIV-infected population was 
significantly lower compared to the APOE E2 allelic frequency in the newborn 
population (n ::: 33, Chi-squared, 2.5, p ::: 0.001). Protective mechanisms were 
previously associated with the APOE E2 allele in HIV (Corder, ,2007; Farrer, 
1997). This decrease in the allelic frequency of APOE E2 in the HIV-infected 











HIV infection. The decrease in the allelic frequency of the APOE E2 allele in the 
HIV-infected population has subsequently been replicated in a follow-up study 
with greater numbers performed by dr Joska on this study population (Joska, in 
press). 
Although the APOE E4 allele did not prove significant in our study as 
hypothesized, the APOE genotype may playa role in the pathogenesis of HIV-












Neuroinflammation is involved in the pathogenesis of HIV-associated dementia 
through indirect neuronal injury. Several previous studies found associations 
between systemic inflammation and markers of inflammation in the brain (Honjo, 
2009). These studies originated predominantly from North America and Europe, 
leaving Africa, with its significant burden of HIV, unexplored. This study is, to our 
knowledge, the first in Africa to investigate the relation of systemic inflammation to 
brain inflammation in HAD with clinical, biochemical and neuroimaging techniques. 
We found a significant correlation between systemic inflammatory markers and the 
degree of cognitive impairment in HAD in a dose dependent way. Participants with 
severe cognitive impairment had higher levels of IL-1 beta compared to 
participants with mild cognitive impairment and participants without cognitive 
impairment. The increase in levels of systemic markers of inflammation, which rise 
in conjunction with impaired cognitive function in patients with HAD, suggest a 
causal relationship between systemic infection and cognitive impairment in HAD, 
but will need to be validated in a longitudinal study. 
Inflammatory markers in the peripheral blood correlated significantly with markers 
of inflammation on MRS. We found significant correlations between systemic 
oxidative stress and cognitive impairment associated with inflammation in the brain 
in HAD. The direct association between systemic markers of oxidative stress and 
brain inflammation, and the inverse relationship between anti-oxidant capacity and 
inflammation in the brain, support the involvement of systemic oxidative stress in 
the neuropathogenesis of HAD. These findings support our hypothesis on the 
association between systemic inflammation oxidative stress and inflammatory 











Systemic inflammation and inflammation in the brain may interrelate, as suggested 
by the findings of our study. Systemic inflammation may induce inflammation in the 
brain in a complex bi-directional relationship, resulting in indirect injury and 
neurodegeneration due to the associated inflammatory response (Combrinck, 
2002; Cunningham, 2005). Development of central inflammation secondary to 
systemic inflammation may predispose HIV-positive patients in particular to 
accelerated cognitive decline due to the increased prevalence of opportunistic 
infections in the immune-compromised HIV-infected host. 
The influence of the association between inflammatory markers and cognitive 
decline in HAD will need to be assessed in the long term. The significance of the 
association between the markers of inflammation and the pathogenesis of HIV-
associated cognitive impairment found in this study, and whether it predicts 
prognosis in HAD, remains to be confirmed. Th  relationship between systemic 
infection, systemic inflammation and cognitive impairment due to brain 
inflammation may prove to be an important underlying pathogenesis in HAD. 
We are in need of surrogate markers to assess disease severity, progression of 
disease, response to management in HAD. Monitoring of the inflammatory process 
with systemic markers, similar to the markers in our study, will allow advancement 
in treatment options and prevention of cognitive impairment in HAD. Therapeutic 
options, including HAART, might address the underlying inflammatory cause, with 
modification of the disease process and reversal or even prevention of cognitive 
impairment. 
The advent of HAART attenuated neurological complications of HIV, but the 
burden of HIV associated neurocognitive impairment persists despite therapy. 
HAART has the possibility to reverse cognitive impairment in HAD, making early 











associated with increased peripheral cytokines is reversible or not. Systemic 
inflammation may lead to temporary neuronal dysfunction which could be reversed 
if systemic inflammation and immune activation is reduced. As many of the 
participants of this study would have subsequently gone on to HAART, re-
evaluation of systemic inflammation, and the associated inflammatory changes in 
the brain in these participants while on HMRT, will be of interest. The association 
between systemic inflammation and cognitive impairment in HAD may be 
reversible on HMRT. 
The frequency of the APOE E4 allele in our study resembled the high frequency of 
the APOE E4 allele found in other studies performed in Africa (Sand holzer, 1995). 
The frequency of the APOE E4 allele is much higher than numbers stated in 
Western populations (Corder, E.H., 1998; Farrer, L.A., 1997). The high 
prevalence of the APOE E4 allele may predispose HIV-infected African individuals 
to a disproportionate risk of cognitive impairment. Our study did not find an 
association between the APOE E4 allele and either markers of systemic 
inflammation, systemic oxidative stress and inflammation in the brain or cognitive 
impairment in HIV-positive participants. This might be due to a lack of sufficient 
numbers. The APOE E2 allele was significantly less frequent in the HIV-positive 
group compared to the newborn controls. This may imply a protective role of the 
E2 allele against cognitive impairment in HAD. Research conducted on larger 
numbers of the same population has subsequently supported this finding (Joska, 
2010). Longitudinal studies need to clarify the relationship between the APOE E2 
allele and HAD. 
Limitations of the study include a small number of participants and the cross-
sectional nature of the study. I initiated this as a pilot study, which has 
subsequently developed in a longitudinal study. Some of our results have already 











Due to the cross-sectional nature of the study. we could only investigate 
associations between inflammation and HAD. Longitudinal studies will need to 
assess the causal relationship between systemic inflammation and brain 
inflammation in HAD. 
Although we attempted to exclude active systemic and opportunistic central 
nervous system infections on screening. we could not exclude all possible 
infections. We did not have permission to perform lumbar punctures to exclude the 
presence of an infectious cause of central nervous system inflammation. Systemic 
inflammatory markers correlated with the systemic oxidative stress markers. This 
supports the presence of systemic inflammation. Seeing that we relate systemic 
inflammation to inflammation in the brain, any systemic infection able to mount a 
systemic inflammatory response, regardless of etiology, may be involved in 
inflammation in the brain and neurodegeneration. This might rectify the unknown 
presence of opportunistic infections, because they add to systemic inflammation 
nonetheless, and we are measuring systemic inflammation as common 
pathogenesis, independent of cause. 
In conclusion, we found significant relationships among markers of systemic 
inflammation, systemic oxidative stress and inflammation in the brain on MRS in 
patients with HAD. The complexity of the respective relationships among systemic 
inflammation, oxidative stress and neuroinflammation, as determined in our study, 
is depicted in figure 12; a summary of our findings on inflammation in HAD. 
This study is, to our knowledge, the first in Africa to investigate the role of 
neuroinflammation in HAD with the use of systemic markers of inflammation and 
neuroimaging in relation to the APOE genotype. In this study systemic 
inflammation and oxidative stress showed significant associations with 











I initiated this study to investigate the role of inflammation in the 
neuropathogenesis of HAD through evaluation of systemic markers of 
inflammation and oxidative stress, markers of inflammation in the brain on MRS 
and their correlation with cognitive impairment. This study served as a pilot study 
for what has since developed into a longitudinal study conducted by the 
Department of Psychiatry (Dr John Joska), UCT, in collaboration with Assoc Prof 
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